Title: Bispectral I ndex a nd Levels o f Sedation wi th Propofol w ith/without Remifentanil in Healthy 
Volunteers ( SONORA) 
Document: Pr otocol  
Identifier: [STUDY_ID_REMOVED] 
Date: 28SEP2020
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 1 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
    
Clinical Investigation Plan  
Clinical Investigation Plan/Study Title   
(SONORA)  
Clinical Investigation Plan Identifier  MDT19049SONORA  
Study Product Name  [CONTACT_231032]™ Complete Monitoring System  
Sponsor/Local Sponsor  Medtronic  
Minimally Invasive Therapi[INVESTIGATOR_634789] (MITG)  
Respi[INVESTIGATOR_696], Gastrointestinal & Informatics (RGI)  
[ADDRESS_847749], 
Boulder, CO [ZIP_CODE] 
U.S.A.  
Document Versi on  5 
Version Date  28 Sep 2020  
Principal Investigator(s)  David MacLeod, FRCA  
Human Pharmacology & Physiology Lab Duke University Medical Center  
Durham, NC [ADDRESS_847750] Name  [CONTACT_231032]™ Complete Monitoring System  
Sponsor  Medtronic  
Minimally Invasive Therapi[INVESTIGATOR_634789] (MITG)  
Respi[INVESTIGATOR_696], Gastrointestinal & Informatics (RGI)  
Clinical Investigation Plan Identifier  MDT19049SONORA  
Version Number/Date  5/ [ADDRESS_847751] of the clinical investigation without the prior written consent of Medtronic.  
I will provide all study personnel under my supervision copi[INVESTIGATOR_232376]. I will discuss this material with them to ensure that they are fully 
informed about the products and the study.  
Investigator’s Signature:   
[CONTACT_10670]’s Name:   
[CONTACT_16277]:   
Date:    
  
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 3 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  Table of Contents  
 
1. Investigator Statement  ................................................................................................ ...... 2 
Table of Contents  ................................................................................................ ......................  3 
Table of Tables  ................................................................................................ .......................... 6  
Table of Figures ................................................................................................ .........................  6 
2. Glossary ................................................................................................ ..............................  8 
3. Synopsis  ...........................................................................................................................  10 
4. Introduction  .....................................................................................................................  17 
 Background  ........................................................................................................................  17 
4.1.1.  Basics of Anesthesia & Anesthetics  ...............................................................................  17 
4.1.2.  EEG Monitoring in Anesthesia  ...................................................................................... 18 
4.1.3.  Clinical Summary ........................................................................................................  20 
 Purpose  .............................................................................................................................. 20 
5. Obj
ectives  ........................................................................................................................  21 
 Objectives  ..........................................................................................................................  21 
5.1.1.  P
rimary Objective(s)  ...................................................................................................  21 
5.1.2.  Secondary Objective(s)  ...............................................................................................  [ADDRESS_847752] Description .......................................................................................................... 22 
 General  .............................................................................................................................. 22 
 Manufacturer  ...................................................................................................................... 23 
 Packaging  ........................................................................................................................... 23 
 Intended Popu lation  ............................................................................................................ 23 
7.4.1.  B
IS™ Complete Monitoring System  ..............................................................................  23 
7.4.2.  BISx4™ Modules ........................................................................................................  24 
7.4.3.  Patient Interface Cable  ...............................................................................................  25 
7.4.4.  BIS™ Bilateral Sensor  ................................................................................................ . [ADDRESS_847753] Monitoring Technology  ...................................................... 26 
7.5.3.  Site’s Equipment/Supplies  ........................................................................................... [ADDRESS_847754] Accountability  .................................................................................................... 27 
8. Stu
dy Site Requirements  ................................................................................................ . 28 
 Investigator/Investigation Site Selection  ................................................................................  [ADDRESS_847755] Consent  ............................................................................................................ 33 
 Baseline/ Enrollment - Visit 1  ..........................................................................................  34 
 Execution – Visit 2  ......................................................................................................... 35 
10.5.1.  P
rior to Procedure  ...................................................................................................  35 
10.5.2.  Procedure – Visit 2 and Visit 3  ..................................................................................  35 
 Follow -up ...................................................................................................................... 38 
10.6.1.  P
hone Call  ..............................................................................................................  38 
 Assessment of Efficacy  ...................................................................................................  38 
 Assessment of Safety  .....................................................................................................  38 
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 5 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  
 Recording Data ..............................................................................................................  39 
 Role of Sponsor’s Representatives  ...................................................................................  [ADDRESS_847756] Exit From Study  ..........................................................................................  41 
11. Risks and Benefits  .........................................................................................................  41 
 Potential Risks  ...............................................................................................................  41 
11.1.1.  BIS
™ Sensor Risks .................................................................................................. 42 
11.1.2.  BIS™ Monitoring System Risks  ................................................................................. [ADDRESS_847757] Complaint Reporting  ..........................................................................................  55 
13. Dat
a Review Committees  ..............................................................................................  55 
14. Statistical Design and Methods  .....................................................................................  56 
 Sample Size Justification  ................................................................................................  56 
 Analysis Populations  ....................................................................................................... 56 
 Statistical Methods  ......................................................................................................... 56 
15. Eth
ics .............................................................................................................................  57 
 Statement(s) of Compliance  ........................................................................................... [ADDRESS_847758] Access to Source Data/Documents  .................................................................. [ADDRESS_847759]  Retention  ...........................................................................................................  62 
16.8.1.  Inve
stigator Records  ...............................................................................................  62 
16.8.2.  Sponsor Records  .....................................................................................................  63 
 Reporting Requirements  ................................................................................................ . 64 
16.9.1.  Inve
stigator Reports  ................................................................................................  64 
 Publication and Use of Information  ..................................................................................  64 
 Suspension or Early Termination  .....................................................................................  65 
17. Referenc
es .....................................................................................................................  67 
18. Appendices  .................................................................................................................... 71 
Appendix A - Modified Observer's Assessment of Alertness/Sedation scale  ....................................... 71 
 
19. Version History  ..............................................................................................................  75 
 
Table of Tables  
Table 1: Clinical Data from Literature  ......................................................................................................... 20 
Table 2 : Schedule of Events  ........................................................................................................................ 3 1 
Table 3: Possible Side Effects using Medication  .......................................... Error! Bookmark not defined. 7 
Table 4: Definition of Adverse Events and Device Deficiency  .................................................................... 49 
Table 5: Adverse Event Classification Responsibilities …………………………………………………………………………… 52 
Table 6:  Repo rting Requirements for Events …………………………………………………………………………………………. 52 
Table 7:  Investigator reports applicable for all geographies per Medtronic requirements ……………………..6 3 
Table of Figures  
Figure 1: BIS ™ Range Guidelines; a general association between clinical state and BIS values  .............  19 

Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 7 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  Figure 2: The BIS ™ Complete Monitoring System. 1 – Monitor Interface Cable; 2 – BIS™ Monitor; 3 - 
BIS™ bilateral sensor will be used; 4 - Patient Interface Cable (PIC); 5 - BISx4™ (LoC 4 Channel) ..........  24 
Figure 3: BISx4™ – 1- Monitor Interface Cable connects to Monitor; 2- Patient Interface Cable connects 
to BIS ™ sensor; 3 - BISx4™ (BIS LoC 4 Channel)  ............................................................................ 254 
Figure 4: BIS ™ Bilateral Sensor  .....................................................................................................  265 
Figure 5: Schematic Representation of Procedure Schedule  .............................................................  355 
  
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 8 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  2. Glossary 
Term  Definition/Acronyms 
AE Adverse Event.  
ASA American Society of Anesthesiology  
BIS™ Bispectral Index (BIS) technology monitoring uses processed EEG signals to measure sedation depth based on 
the level of consciousness  
CBC Complete Blood Count  
CO [ADDRESS_847760]. Capnograph outputs numeric values and waveforms of the 
fractioned concentration of CO 2 of each breath  
CRF Case Report Form. Forms where the clinical data are collected. eCRF is the electronic version of the CRF  
EC Ethics Committee  
ECG Electrocardiogram. A diagnostic tool that measures and records the electrical activity of the heart  
ED Effective dose  
EDC Electronic Data Capture. E lectronic system s where the data are collected through the eCRF (Oracle Clinical). 
May also be referred to as RDC (Remote Data Capture).  
EEG Electroencephalogram 
ET End-tidal concentration  
EMR  Electronic Medical Record. Digital version of a patient’s medical record within a single facility.  
EtCO [ADDRESS_847761] 
ISF Investigator Site File. Regulatory binder supplied by [CONTACT_634817]19049SONORA Version  5.0 Page 9 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  Term  Definition/Acronyms 
LOC Level of consciousness  
MOAA/S  Modified Observer ’s Assessment of Alertness/Sedation 
NCM Non -contact [CONTACT_634818] [INVESTIGATOR_678]. The person  is responsible for overseeing the study and assuring study completion in 
compliance with  applicable regulations. 
PIC Patient Interface Cable  
PK/PD  Pharmacokinetics and pharmacodynamics  
RA Regulatory Authority  
SpO [ADDRESS_847762]  
  
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 10 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  3. Synopsis  
Title  Bispectral Index and Levels of Sedati on with Pr opofol with/without Remifent anil 
in Healthy Volunteers ( SONORA)   
Clinical Study Type  Prospective   
Product Name  [CONTACT_231032]™  Complete Monitoring System  
Product Status  BIS™ is commercially available in the [LOCATION_002] . 
Sponsor  Medtronic   
Minimally Invasive Therapi[INVESTIGATOR_634789] (MITG)  
Respi[INVESTIGATOR_696], Gastrointestinal & Informatics ( RGI) 
[ADDRESS_847763]  
Boulder, CO [ZIP_CODE]  
Investigation 
Purpose  To investigate the relationship between BIS ™ and propofol with/ without 
remifentanil across a wide range of hypnotic states. 
Primary Objective  To determine BIS 50 (BIS™ value at which 50% of patients will be unresponsive at 
given drug concentrations)  
Secondary 
Objective  To determine BIS 95 (BIS™ value at which 95% of patients will be unresponsive at 
given drug concentrations)  
To determine Prediction Probability (P k) for correctly predicting if the subject was 
responsive or unresponsive  
Study Design  This is a single-center, prospective, non -randomized, cross -over study to collect 
data to evaluate the relationship between BIS ™ and anesthetic regimens. The 
subjects  will receive two regimens of anesthesia with different drug 
combinations, with at least a 1 -week washout period between regimens. 
Subjects  will be sequentially assigned to start with either Propofol (P) or Propofol 
with 4 ng/ml of Remifentanil (R) regimens with the BIS™ bilateral sensor placed 
on the subject’s forehead. The Modified Observer's Assessment of 
Alertness/Sedation (MOAA/S) scale will be used to measure the level of alertness 
in sedated subjects, with Tetanic Electrical Stimulation (TES)  being used  once the 
patient is unresponsive to tactile stimuli  (e.g., MOAA/S  < 2). The loss of tactile 
stimulus  response will be defined according to the MOAA/S score  value  <2.  
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.[ADDRESS_847764] reaches an MOAA/S <2, with a one -
time stimulation of 50mA , [ADDRESS_847765]’s response 
will be recorded along with the BIS™ value prior to stimulation, at the time of 
stimulation and [ADDRESS_847766]’s  level of sedation,  pre-TES and post -
TES. 
 
  
  
Sample Size  To collect [ADDRESS_847767] dropouts.  Based on the dose-response 
Hill equation with an allowable error of ± 15% for BIS 50 and coefficient of 
variation of 25% at the alpha level of 0.05, the sample size will provide sufficient power (>80%) to evaluate the performance of anesthetic agents/ regim ens.
   
Duration  The study duration is expected to be up to approximately [ADDRESS_847768] will be approximately  (~) [ADDRESS_847769] will be contact[CONTACT_30781] 48 hours of the study participation.  
 
Planned number of 
sites  1 site in the US  
Inclusion/Exclusion 
Criteria  Inclusion Criteria: 
1. Healthy (ASA physical status 1), male or female subjects between the 
ages of 18 to 60 years;  
2. Completion of a health screening for a medical history by a licensed 
physician, nurse practitioner or physician assistant ; 
3. Vital signs must be within the following ranges to be included : Vital signs 
measured sitting after [ADDRESS_847770]; heart rate: 45-90 bpm; systolic 
blood pressure: 110-140; diastolic blood pressure: 50 -90. Out-of -range 
vital signs may be repeated once. [Pre -dose vital signs will be assessed 
by [CONTACT_079] [INVESTIGATOR_1461] (e.g., a medically qualified sub-
investigator) before study drug administration. The Principal Investigator 
[INVESTIGATOR_634790]];  
Exclusion Criteria:  
1. Has severe contact [CONTACT_634819] a reaction to standard 
adhesive materials found in pulse oximetry sensors, ECG electrodes, 

Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 12 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  respi[INVESTIGATOR_230882], or other medical sensors [self -
reported];   
2. Known neurological disorder (e.g., epi[INVESTIGATOR_002], the presence of a brain 
tumor, a history of brain surgery, hydrocephalic disorders, depression 
needing treatment with anti -depressive drugs, a history of brain trauma) 
[self-reported and assessment by [CONTACT_976] [INVESTIGATOR_9232]];  
3. Known cardiovascular disease (e.g., hypertension, coronary artery 
disease, prior acute myocardial infarction, any valvular and/or 
myocardial disease involving a decrease in ejection fraction, 
arrhythmias, which are either symptomatic or require continuous 
medication/ pacemaker/ automatic internal cardioverter defibri llator) , 
current implanted pacemaker or automatic internal cardioverter 
defibrillator [self-reported and assessment by [CONTACT_976] [INVESTIGATOR_9232]];  
4. Has a clinically significant abnormal finding on medical history, physical 
examination, clinical laboratory tests, or ECG at the screening [self -
reported and assessment by [CONTACT_976] [INVESTIGATOR_9232]];  
5. Recent use of psychoactive medication (e.g., benzodiazepi[INVESTIGATOR_1651], 
antiepi[INVESTIGATOR_006], ADHD medication, Parkinson’s medication, anti -
depressant drugs, opi[INVESTIGATOR_2438]) [self -reported and assessment  by [CONTACT_976] [INVESTIGATOR_42550]];  
6. Subjects with known gastric diseases [self -reported and assessment by 
[CONTACT_976] [INVESTIGATOR_9232]];   
7. Has a positive urine cotinine test or urine drug screen or oral ethanol test 
[POC testing];  
8. Known history of allergic or adverse response to drugs  to be 
administered [self -reported];   
9. Known history of complications relating to previous general anesthesia 
or conscious sedation [self -reported and assessment by [CONTACT_976] [INVESTIGATOR_9232]];   
10. Known history of malignant hyperthermia [self -reported and assessment 
by P I or delegate];  
11. Has a room air saturation less than 95% by [CONTACT_406] [measurement 
by [CONTACT_976] [INVESTIGATOR_9232]];  
12. Has a clinically significant abnormal ECG [assessment by [CONTACT_976] [INVESTIGATOR_9232]];  
13. Has a clinically significant abnormal pulmonary function test via 
spi[INVESTIGATOR_038] [assessment by [CONTACT_976] [INVESTIGATOR_9232]];  
14. Pregnant or lactating women [assessed by [CONTACT_230955] -reported];   
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 13 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  15. Subjects with tattooed skin specific to the sensor placement areas 
(forehead, fingers, chest) [self- reported and assessment by [CONTACT_976] [INVESTIGATOR_42550]];  
16. The subject must not take any prescription medication, except female 
hormonal contraceptives or hormone replacement therapy, from 14 6 
days before the dosing until the end -of-study visit without evaluation 
and approval by [CONTACT_737]. Subjects who participated in a previous 
clinical trial who received a required FDA approved concomitant 
medication, for example, naltrexone, but were not randomized may be 
considered for participation in this study if they meet the washout 
requirement [assessment by [CONTACT_976] [INVESTIGATOR_634791]]; 
Study Procedures 
and Assessments  Prescreening Visit: 
• Online or phone call pre-screening survey  
Enrollment  Visit (Visit 1) : 
• Informed Consent Process 
• Demographics  
• Medical screening  
• Medical history 
• Physical E xamination  
• ASA physical assessment  
• Electrocardiogram (ECG)  
• Complete Blood Count (CBC)  
• Urine  testing for presence of:  
• Cotinine (nicotine metabolite)  
• Pregnancy - for female subjects of childbearing age  
• Concomitant Medication Collection  
The subject will be instructed not to consume beverages and foods containing 
alcohol, grapefruit, or caffeine/  xanthine prior to dosing until the end -of-study 
visit per Institutional guidance. All subjects  will fast as it will be instructed by [CONTACT_634820]. The per 
dosing instructions will be provided to the subject.  
Subjects who meet all of the inclusion criteria and none of the exclusion criteria will be enrolled.  
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 14 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  Procedure Visit:  
Pre-Procedure Assessments  (Visits 2 & 3) : 
• Vitals 
• Urine  testing for presence of:  
• Cotinine (nicotine metabolite)  
• Drugs and Alcohol  
• Pregnancy - for female subjects of childbearing age  
• Breathalyzer  
• Concomitant Medication Collection  
• Adverse Event Assessment  
Procedure Assessments  (Visits 2 & 3):  
• BIS™ sensor application and connected to BIS ™ Monitor  
• TES sensor application to the calf with a stimulation of 2mA, 2 Hz  for 
1-5 seconds  provided to ensure proper application  
• EEG waveform recorded in real -time during the stud y 
• IV Catheter Placement for fluid and drug  administration  
• Blood pressure monitoring 
• Continuous EEG, Pulse Oximeter for SpO 2, and EtCO 2 
• Anesthesia Administration  
• The propofol and remifentanil will be administered using the target -
controlled infusion (TCI) computer -controlled program, e.g., TIVA 
Trainer, or another computer -controlled program/pump, to ensure 
that the targeted effect-site concentration of a drug is reached and 
maintained at each drug concentration  plateau 
• 1% p ropofol  and remifentanil  diluted to a single concentration o f 50 
µg/ml will be used for this study. Infusion rate between 0 and 1200 
ml/hr.  will be used to achieve a target effect-site concentration of 
propofol  and remifentanil 
• For propofol, the effect -site concentration for propofol will be 
predicted using Schne ider pharmacokinetics and pharmacodynamics 
(PK/PD) model, and f or remifentanil, Minto PK/PD model will be 
used  
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 15 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  • The assisted ventilation of the subject with either facemask or LMA 
may be used.  
• Each subject  will receive one of the anesthetic regimens. The subj ect 
will rest for ~ 15 minutes before starting any regimen  
• MOAA/S Assessment  
• Once subjects reach a MOAA/S score of <2, they  will receive noxious 
electrical stimulation using Tetanic Electrical Stimulation (TES) . The 
BIS™ value  will be recorded, followed by [CONTACT_230967]/S assessment . 
Then, TES will be  initiated  with one stimulation to the tibial nerve at 
50mA , 50Hz  for [ADDRESS_847771]’s pain avoidance behavior, 
such as withdrawal of extremity, facial grimace or verbal groan, will 
be noted. The BIS ™ value will then be recorded at the time of 
subject’s response and 2 minutes following the TES assessment  
• Adverse Event Assessment  
• Device Deficiency Assessment  
A clinician will be monitoring respi[INVESTIGATOR_634792]. The respi[INVESTIGATOR_634793], adequate 
oxygenation (SpO 2 >92%), and CO [ADDRESS_847772] (with or without manually assisted breathing),  insertion of an airway device 
(oropharyngeal airway or laryngeal mask airway) and/or intermittent positive 
pressure ventilation (IPPV).  Mask or nasal cannula will be used for supplemental 
O2 delivery.  
For Propofol  group , the initial target effect -site concentrations of propofol will 
be 0.5 µg/ml followed by [CONTACT_634821]-site 
concentrations of 1.5, 2, 2.5, 3, 4, 6, and  a maximum of  8 µg/ml until a BIS™ value 
not less than 30 is reached  or per Investigator’s discretion . The BIS ™ value should 
not intentionally be taken below 30. The equilibration time for each targeted 
effect-site concentration will be at approximately  12 minutes. The BIS ™ value  
and MOAA/S scale  will be assessed when the patient is awake and at different 
propofol concentrations. TES  will then be initiated  following the MOAA/S 
assessment and  once the subject reaches a MOAA/S  <2. The BIS ™ value will be 
recorded at the time of subject’s response and  2 minutes following the TES 
assessment . The propofol concentration will be decreased by [CONTACT_634822] s with BIS ™ values and MOAA/S assessments being 
captured . 
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.[ADDRESS_847773]-site targeted concentration of remifentanil of 4 ng/ml, remifentanil will be 
given by a continuous inf usion. Within a pproximately [ADDRESS_847774]-site concentration of 
remifentanil of 4 ng/ml throughout the study. The equilibration time for each 
targeted plateau will be approximately  12 minutes. The BIS ™ value  and MOAA/S 
scale  will be assessed when the patient is awake and at different propofol 
concentrations. TES  will then be initiated following the MOAA/S assessment once 
the subject reaches a MOAA/S <2 . The BIS ™ value will be recorded  approximately  
2 minutes following the TES assessment . 
The cardiac output will be monitored, and subjects could be discontinued per PIs discretion. The respi[INVESTIGATOR_113056], a respi[INVESTIGATOR_135890] 4 
breaths/min ute or less will be considered evidence of respi[INVESTIGATOR_312530], and 
remifentanil will be discontinued. 
The start time of any drug infusion, target effect-site concentrations  and infusion 
rate will be noted in the  electronic Case Report Forms (e CRFs ). The BIS ™ value  
prior to MOAA/S assessment  and TES  will be noted along with the BIS™ value  at 
the time of subject’s response and [ADDRESS_847775] management during the procedure will be recorded .  
The device data (raw signals), including Heart Rate,  Blood Pressure, Respi[INVESTIGATOR_634794], EtCO
2, SpO 2, BIS™, TCI , if available, will be recorded in real- time during the 
procedure and files will be provided to Medtronic  by [CONTACT_779].  The instructions on 
the secure data transfer will be provided by [CONTACT_13735].  
Each subject will be contact[CONTACT_30781] [ADDRESS_847776] a setting that is fully equipped for the monitoring and support of the respi[INVESTIGATOR_634795]. Subjects will be continuously monitored  throughout the study.  
Subjects will be monitored for Adverse Events, Serious Adverse Events,  and 
Device-Related Adverse Events  from BIS™ sensor application throughout the 
follow-up phone call . 
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.[ADDRESS_847777] demographic information and baseline characteristics will be 
summarized using descriptive statistics. For safety assessments, adverse events 
(AEs) will be summarized using frequency counts and percentages. Descriptive 
statistics will be provided by [CONTACT_231001] .  
The primary effectiveness analysis will be based on all evaluable data collected 
from the left side of the brain to reflect the typi[INVESTIGATOR_230934] . The BIS ™ index value collected from the right side of the brain will be 
used for research .  
Subjects who discontinue participation prematurely will be included in the 
analysis of results. Subjects who withdraw from the study prior to completing both regimens will be replaced by a new subject . 
The data will be analyzed for each regimen  to evaluate the dose -response 
relationship of the anesthetic agent concentration and BIS ™ values.  
Any subject who responds to any verbal command with MOAA/S assessment score of  2, 3, 4, and 5 will be considered as  responsive. Subjects with MOAA/S 
assessment score s <2 will be considered unresponsive.  
The value of BIS ™ will be assessed at the different targeted-controlled drug 
concentrations or infusion rates . The logistic regression (simplified E max model) 
will be used to analyze the relationship between the BIS ™ index and loss of 
responsiveness through the probability  of response curves. The v alues of BIS™, 
at which 50% (BIS 50) and 9 5% (BIS 95) of subjects are unresponsive, and their 95% 
confidential intervals will be derived.  The systematic variance between groups 
will be evaluated. The Prediction Probability score (P k) for correctly predicting if 
the subject was responsive or unresponsive will be assessed.   
4. Introduction  
 Background  
4.1.1.  Basics of Anesthesia & Anesthetics 
General anesthesia (GA) is a reversible state of controlled unconsciousness that is achieved with dru gs 
that prevent awareness, pain, recall, distress , and movement in patients during surgery. General 
anesthesia is performed by [CONTACT_230963], generally anesthesiologists and nurse anesthetists , with 
extensive education and training in the physiology, pharmacology, techniques, and risks involved.  
Two critical  components of general anesthesia are hypnosis and analgesia. Maintaining an adequate level 
of anesthesia depth is critical to the attenuat ion of these responses. The hypnotic component can be 
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 18 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  defined as the probability of tolerance to non-painful stimulus, e.g., name- calling, shaking, and shouting. 
The analgesic component may be considered as the probability of tolerance to a painful stimulus. 
Tolerance means the absence of a response being either a somatic response ( e.g., movement, sweating, 
eye-opening) or a hemodynamic response (increase in heart rate or blood pressure). When the state of 
general anesthesia is inadequate for the level of nociceptive stimulation from surgery, the heart rate and 
blood pressure can increase dramatically, alerting the anesthesiology provider to the possibility of increased nociception and arousal. Higher doses of an anesthetic are necessary to prevent reactions  to 
more intense surgical stimuli. This fact has suggested that different states of anesthesia fall along a continuum of depth, with deeper anesthesia eliminating reactions to stronger stimuli. Thus, the anesthesiologist needs to know when a patient has re ached a depth of anesthesia commensurate with an 
impending stimulus. Very superficial or deep depth levels can be disastrous in both the short and long run. The patient expects a surgical procedure to be safe and painless, with the assurance that throughou t 
the procedure, s/he is asleep, without any perception or memory of what happened during that period. 
Intravenous anesthetics, including propofol, barbiturates , and benzodiazepi[INVESTIGATOR_1651], produce a concentration -
dependent reduction in wakefulness , ultimately le ading to complete loss of consciousness. The effective 
dose ( ED
50) of intravenous anesthetics for obtaining general anesthesia is calculated as the effect -site 
concentration at which [ADDRESS_847778] anesthetic agents appear to cause unconsciousness by [CONTACT_24096], 
directly or indirectly, a posterior lateral corticothalamic complex centered around the inferior parietal 
lobe, and perhaps a medial cortical co re of the brain. [1]  
4.1.2.  EEG Monitoring in Anesthesia  
Since 1939, anesthesiologists have known about changes in the electroencephalogram (EEG) that are  
produced by [CONTACT_167201].[2]  Many of the changes that occur in the brain with changes in anesthetic 
states can be readily observed in unprocessed EEG  recordings.  Different behavioral and 
neurophysiological states induced by [CONTACT_634823].  The 
earliest use of the EEG in anesthesia tested the effects of barbiturates, eventually leading to the recognition of particular sequential effect s shown  in Figure 1 . [3] The first changes induced by [CONTACT_634824] 20 -30 Hz (initial rapid response) waves, followed by [CONTACT_230966] [ADDRESS_847779] as the initial rapid response yields to the slower oscillations . 
Spi[INVESTIGATOR_230894] 5-12 Hz become prominent , and in turn, decline as the EEG develops large polymorphic 
waves of 1-3 Hz. When this slow polymorphic activity becomes d ominant, the patient tolerates skin 
incision. At still higher concentrations of barbiturates, the EEG displays periods of suppression, each 
terminating with “burst” of renewed activity , which contains high-frequency components. The burst 
gradually subsides  as it leads into the next epi[INVESTIGATOR_230895]. This combination of alternating phases 
of high -amplitude and low -amplitude periods is called “burst suppression .”  
Monitoring the depth of anesthesia could help the anesthesia professional avoid intraopera tive 
awareness and help to ensure that an appropriate dose of anesthetic drugs is given for each patient . The 
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.[ADDRESS_847780] blood vessels to maintain normal blood pressure and cardiac output. Overly deep 
anesthesia can also result in respi[INVESTIGATOR_634796] [4]. 
There is no objective scale that measures “too light” or “too deep” anesthesia. Bispectral Index (BIS) 
technology monitoring uses processed EEG signals to measure sedation depth based on level of consciousness (LOC) signals and allows anesthesia providers to titrate general anesthesia to achieve the  
desired LOC on the brain [4, 5] . BIS™ technology  consists of a sensor, a digital signal converter, and a 
monitor. The sensor is placed on the patient’s forehead to pi[INVESTIGATOR_634797]. BIS™ values quantify changes in the 
electrophysiologic state of the brain  during anesthesia. Overall, a BIS ™ value below 60 is associated with 
a low probability of response to commands . The BIS™ is a continuous ly processed EEG parameter that 
correlates to the patient’s level of hypnosis, where 100 = awake and 0 = flat -line EEG.  The BIS™ parameter 
was designed to correlate with “hypnotic” clinical endpoints (sedation, lack of awareness, and memory) and to track changes in the effects of anesthetics on the brain. Figure 1 reflects a general association 
between clinical state and BIS values. Ranges are based on results from a multi -center study [5] of the BIS 
system involving the administration of specific anesthetic agents. BIS ™ values and ranges assume that the 
EEG is free of artifacts that can affect its performance. Titration of anesthetics to the BIS™ range should 
be dependent upon the individual goals established for each patient. These goals and associated BIS ™ 
ranges may vary over time and in the context of patient status and treatment plan.  
 
 
Figure 1: BIS™ Range Guidelines ; a general association between clinical state and BIS™ values 
 

Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 20 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  4.1.3.  Clinical Summary  
The BIS™ system has been on the market for 20 years, and there is a large amount of clinical data available 
to assess the performance and safety of the devic e. Table 1  summarizes overall clinical experience 
regarding the use of the BIS ™ System found on the performance and safety of the device in the published  
clinical literature . The total number of individuals with device experience related to safety data from the 
clinical literature is 7,627. The patient populations included in these studies varied between infants, 
pediatrics, adults, obese adults, and the elderly.  
 
Table 1: Clinical Data from Literature  
Performance Data  Safety Data  
Number of Publications  Number of Patients  Number of Publications  Number of Patients  
32 Publications addressing 
performance  
[6-37] 43,247  11 Publicati ons with safety 
data [7, 10, 16, 22, 23, 25, 31-
33, 38, 39]  7,627  
 
Also , the anesthetic state is achieved with a hypnotic or sedative and an analgesic to provide the absence 
of consciousness, amnesia, and analgesia. Several studies examined and evaluated the usefulness of the 
BIS™ as a measure of the depth of anesthesia [40-42] . The relationship between BIS™ and blood 
concentration of propofol was demonstrated in many studies , and during propofol anesthesia, increasing 
doses of alfentanil or additional administration of nitrous oxide do not affect the BIS ™ value [5, 43, 44] . In 
addition, propofol  and remifentanil are commonly combined for total IV anesthesia. A prospective study 
of 45 adult patients scheduled for elective surgery under general anesthesia was undertaken using BIS ™ 
monitoring to evaluate a pharmacokinetic (PK)  and pharmacodynamic (PD) based model for target -
controlled infusions of propofol and remifentanil  [29]. The Schnider [45, 46] and Minto  [47] models 
include an assessment of both the PK and PD effects of propofol and remifentanil, respectively, and include the covariates of age and BMI.  It demonstrated the effective use of BIS ™ monitoring as a guide 
for evaluating target -controlled infusion -based  anesthesia models. The c linical literature review did not 
identify any new risks/side effects or safety concerns for the target device and its intended indications. The data form published clinical studies included in safety assessment did  not reveal any new 
complications directly related to the use of the devices . 
 Purpose  
To investigate the relationship between BIS™ and  propofol with/ without remifentanil across a wide 
range of hypnotic states .  
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 21 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  5. Objectives  
 Objectives  
5.1.1.  Primary Objective(s)   
To determine BIS 50 (BIS™ value at which 50% of patients will be unresponsive at  a given drug 
concentration) .  
5.1.2.  Secondary Objective(s)  
To determine BIS 95 (BIS™ value at which 95% of patients will be unresponsive at given drug 
concentrations) . 
To determine Prediction Probability (P k) for correctly predicting if the subject was responsive or 
unresponsive. 
6. Study Design  
This is a single-center,  prospective , non-randomized , cross-over study to collect data to evaluate the 
relations hip between BIS™ and anesthetic regimens. The subjects will receive two regimens of anesthesia 
with different drug combinations , with at least a 1 -week washout period between regimens. Subjects will 
be sequentially assigned to start with either Propofol (P) or Propofol with 4 ng/ml of Remifentanil (R) 
regimens  while BIS™ bilateral sensor  placed on the subject’s  forehead. The Modified Observer's 
Assessment of Alertness/Sedation (MOAA/S) scale, refer to Appendix A , will be used to measure the level 
of alertness in sedated subjects  with Tetanic Electrical Stimulation (TES)  being used once subjects reach a 
MOAA /S score <2  and a BIS ™ value of not below 30 or per Investigator’s discretion .  
An anesthesiologist authorized to administer sedation drugs will be responsible for administering any 
procedural drugs for the sedation and monitoring of subject safety and physical state. All other personnel 
involved with the safety  monitoring of subjects mus t be trained in and familiar with the management of 
recovery of sedated patients. The study site should utilize  a setting that is fully equipped for the 
monitoring and support of the subject’s respi[INVESTIGATOR_634798]. Subjects will be 
conti nuously monitored throughout the study.  
 
 
 
 
  

Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.[ADDRESS_847781] 
will be approximately  (~) [ADDRESS_847782] will be contact[CONTACT_634825] 48 hours of the study participation.[6]    
 Rationale  
This clinical study design is formulated in order to capture the performance of BIS ™ with anesthetic agents 
acro ss a wide range of hypnotic states. The study design  is a non-randomized prospective healthy 
volunteer is deemed appropriate in this setting  and will provide more information to confirm the 
performance and safety of the BIS ™.  
 
  
 Propofol  and Remifentanil will be administered as part of an anesthesia technique called total intravenous 
anesthesia (TIVA) that uses computer -controlled infusion pumps in a process called target -controlled 
infusion (TCI). [48] A target effect -site concentration is entered as ng/ml into the pum p, which calculates 
its infusion rate according to the appropriate pharmacokinetic and pharmacodynamic model, which is derived from various patients for model refer to Section 9.5. For remifentanil, the induction levels of 4 
ng/ml are commonly used  in surgeries , but the levels generally vary between 2 -8 ng/ml .[48, 49]  For 
purposes of this study , the selected target effect -site concentration of 4 ng/ml of remifentanil will be 
reasonable and not associated with an increased risk of adverse events . This concentration deemed to be 
appropriate for concentration -based drug effects for remifentani l in health y volunteers .  
7. Product Description  
 General  
The BIS ™ complete monitoring system is a user -configurable patient monitoring system designed to 
monitor the hypnotic state of the brain based on the acquisition and processing of EEG signals. The BIS ™ 
complete system processes raw EEG signals to produce a single number, called the BIS™ index, which 
correlates with the patient's level of hypnosis. A sensor placed on the patient’s head transmits EEG signals 
to the BISx4 ™ unit. The BISx4 ™ unit filters and digitizes the signal , analyzes it for the artifact, and proces ses 
it using digital signal processing techniques  to derive processed EEG parameters like BIS ™, and finally  
sends the processed data to the monitor for display. The purpose of processing the EEG waveform data is 
to extract characteristic features from the complex signal that the BIS algorithm can utilize to derive BIS™. 

Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 23 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  
 Manufacturer 
BIS™ Complete Monitoring System, BISx4 ™, Patient Interface Cable (PIC)  and BIS™ Sensor  
by ([ADDRESS_847783], Mansfield MA) Medtronic Inc.  
 Packaging 
The Sponsor is responsible for the packaging and labeling of the device for shipment to the study site.  
Research conducted for this study will utilize investigational devices  and devices cleared through the 
510(k) regulatory process. FDA cleared devices  are being used within the FDA -cleared indications for use  
(IFU)  and do not require special labeling.  
 
While exempt from Investigational Device E xemption (IDE) submission as a non -significant risk device 
under [ADDRESS_847784] for marketing the devi ce (e.g., 
510(k)) . The device will be labeled with the following: 
 “CAUTION - Investigational Device. Limited by [CONTACT_4496] (or the [LOCATION_002]) Law to investigational use.”   
 It is the investigator’s responsibility to ensure the appropriate labeling is visible and remains intact throughout the life of the stud y. 
 All FDA-cleared equipment associated with the clinical study will be identified with visible markings 
stating, “For clinical trial use only.” Labeling of devices will be provided in accordance wit h local language 
requirements. 
 Intended Population  
7.4.1.  BIS™ Complete Monitoring System  
The BIS™ EEG complete monitor system is intended for use under the direct supervision of a licensed healthcare practitioner or by [CONTACT_230969]. The s ystem and all its associated 
parameters are intended for use on adult and pediatric patients within a hospi[INVESTIGATOR_88355] , 
providing patient care to monitor the state of the brain by [CONTACT_230970]. The BIS ™ index, 
one of the Complete Monitor output parameters, may be used as an aid in monitoring the effects of certain anesthetic agents; and its usage with certain anesthetic agents may be associated with a reduction in primary anesthetic use and a reduction in emergency and recovery time. Use of the BIS ™ index for 
monitoring to help guide anesthetic administration may be associated with the reduction of incidence of awareness with recall in adults during general anesthesia and sedation.  The BIS™ Complete Monit oring 
System includes: 
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 24 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  • BIS™ Complete Monitor  
• BISx4 ™ (BISx4 ™ will be used in this study)  
• Patient Interface Cable (PIC)  
• BIS™ Sensor  
 
Figure 2: The BIS ™ Complete Monitoring System. 1 - Monitor Interface Cable; 2 - BIS™ Monitor; 3- B IS™ bilateral sensor; 4- 
Patient Interface Cable (PIC); 5- BISx4™ (LoC 4 Channel)  
7.4.2.  BISx4™ Module s 
The BISx4 ™ receives, filters, digitizes , and processes patient EEG signals. It is located close to the patient's 
head, where the EEG signal is less subject to interference from other medical equipment. The BISx4 ™ is 
shown in Figure 3 . Its long flexible Monitor Interface Cable connects to the front of the monitor. The 
Patient Interface Cable (PIC) connects the BIS ™ sensor to the BISx4 ™. The attachment clip on the BISx4 ™ 
is used to secure it in a  convenient location near the patient's head.  The BIS x4™ Module is a variant of the 
BISx™ Module, and it  processes up to four channels of EEG data. In this study, BIS x4™ Module  will be used 
with Bilateral Sensor . 

Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 25 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
   
Figure 3: BISx4™ - 1- Monitor Interface Cable connects to Monitor; 2 - Patient Interface Cable connects to BIS ™ sensor; 3 - 
BISx4TM (BIS™ LoC 4 Channel)   
 
7.4.3.  Patient Interface Cable  
Covidien BIS™ Sensor Patient Interface Cable (PIC) connects the BISx4 ™ to the BIS ™ Sensor, refer to  Figure 
3. 
7.4.4.  BIS Bilateral Sensor  
The sensor is the single- use comp onent of the BIS ™ Monitoring System and should be replaced after each 
use. BIS ™ Bilateral Sensor s are designed with a 6 electrode pre -gelled EEG electrode array that is applied 
directly to the patient’s forehead to transmit EEG signals to the BISx4 ™ Module. When the System is 
connected to a BISx4 ™ module and a BIS™ Bilateral Sensor, the monitor displays four channels of EEG.  
The sensor will be applied per IFU.  
 
  

Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 26 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  Figure 4: BIS™ Bilateral Sensor  
 Equipment  
7.5.1.  Other Equipment  
Additional equipment such as FDA -cleared Pulse Oximeter  (SpO 2 sensors and N600x monitors or other) , 
capnography devices , a STIMPOD™ NMS450X nerve stimulator and TOF monitor may  be provided by [CONTACT_634826].  
 
 
 
 
 
  
7.5.3.  Site’s Equipment /Supplies  
Propofol and remifentanil will be provided by [CONTACT_779] . The remifentanil and propofol  will be administered 
using the target- controlled infusion (TCI) computer -controlled program, e.g., TIVA Trainer, or another 
computer -controlled program/pump . In addition , the four monitors (Nexfin, Covidien Capnostream, 
ADInstruments Bio Amp FE132 & Oximeter Pod ML320/F) are integrated into ADInstruments PowerLab. 
This is connected to a Mac computer on which the software program, ADInstruments LabChart v8, is used 
to collect  the data output from the PowerLab. Any additional monitors may be used as needed. All 
monitors will be used per site’s guidance or practice . 
 Product Use  
A member of the Medtronic team will set up the BIS ™ system at each participating research site  or will  
guide the site in set up remotely  in order to ensure all equipment is fully functional. Specific instructions 
for the Site Investigator  and staff  on system set up, use sensor application, and data transfer will be 
provided  before subject enrollment.  
 Produ ct Training Materials  
Prior to  site activation or subsequent involvement in clinical study activities, Medtronic will provide clinical 
study training relevant and pertinent to the involvement of personnel conducting clinical study activities 
and investigat or responsibilities.  Principal Investigators participating in the clinical study and the 
associated clinical study staff will receive training on the device and system (including  but not limited to  
device characteristics, storage requirements, warnings, pr ecautions, and contraindications.)   

Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 27 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  It is the responsibility of the Principal Investigator [INVESTIGATOR_634799] ( e.g., Study Coordinators, Study Nurses, Sub-Investigators, etc.) have been 
appropriately trained, training documented and included on the Delegation of Authority Log. 
 Product Receipt and Tracking 
The investigator or designee will maintain records of devices/products or products provided by [CONTACT_634827], e.g., device shippi[INVESTIGATOR_59309]. The following records will be 
maintained at a minimum for product delivery, receipt , and tracking at the site: dates, quantities received, 
lot/serial numbers, and expi[INVESTIGATOR_1659], as applicable .  
 Product St orage 
Devices/products or products provided by [CONTACT_230973] a secured area. The 
method of storage shall prevent the use of devices/products for other applications than mentioned in this Clinical Investigation Plan. In addition , all information for the use, storage , and handling of the 
device/product as indicated in the IFU  and User Manual must be taken into account.  
 
 Product Return 
Any devices provided by [CONTACT_230974], and all monitors and accessories should be retu rned 
to Medtronic and documentation of return  should be maintained . Non-functioning investigational devices 
must be returned to Medtronic as soon as possible for investigation. Instructions for returning the device 
will be provided.  
 Product Accountability  
Devices/products will be traced during the clinical study  by [CONTACT_230975]  (or lot numbers) 
assigned  to each device/product. The investigator is responsible for the maintenance of a Product 
Accountability Log in the Investigator Site File. On this log, the receipt, use, return, and disposal of the 
investigational devices/products shall be documented. At the end of the clinical study , the principal 
investigator [INVESTIGATOR_634800].  
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 28 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  8. Study Site Requirements  
 Investigator/Investigation Site Selection 
All investigators managing the subject’s anesthesia must be qualified practitioners and experienced in the 
diagnosis and treatment of subjects undergoing general anesthesia.  All physicians must be experienced 
and/or trained in the handling of BIS™ Complete Monitoring System.  
The role of the principal investigator [INVESTIGATOR_54365] -to-day conduct of the clinical 
investigation as well as ensure data integrity and the rights, safety and well- being of the subjects involved 
in the clinical investigation.  
The principal investigator [INVESTIGATOR_67417]: 
• Be qualified by [CONTACT_8640], training, and experience to assume responsibility for the proper conduct of the clinical investigation  
• Be experienced in the field of application and training in the use of BIS™ Complete Monitoring 
System 
• Disclose potential conflicts of interest, including financial, that interfere with the conduct of the clinical investigation or interpretation of results  
• Be able to demonstrate that the proposed investigational study site:  
 Has the required number of eligible subjects needed within the recruitment period  
 Has one or more qualified investigators, a qualified investigational study site team and adequate facilities for the foreseen duration of the clinical investigation  
Study site personnel training will be completed and documented prior to participation in this study.  
 Study Site Activation 
During the activation process (prior to subject enrollment), Medtronic will train study site personnel on 
the clinical investigation plan, on relevant standards and regulations, informed consent, and on da ta 
collection and reporting tools. If new members join the study site team, they will receive training on the applicable study requirements relevant to their role before contributing to the study.  
Prior to performing study related activities, all regulatory requirements shall be fulfilled, including, but not limited to the following:  
• IRB approval (and voting list, as required by [CONTACT_1769]) of the current version of the CIP and IC 
• RA approval or notification (as required per local law)  
• Fully executed CTA  
• Financial disclosure (if applicable)  
• CV of investigators and key members of the investigation study site team (as required)  
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 29 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  • Documentation of delegated tasks  
• Documentation of study training.  
• Additional requirements imposed by [CONTACT_427], the IRB  and RA shall be followed, if 
appropriate.  
In addition, all participating study site staff must be trained on the current version of the CIP as well as on 
the applicable study requirements depending on their role and must be delegated by [CONTACT_1961] [INVESTIGATOR_180984].   
Medtronic will provide each study site with documentation of study site/investigator readiness; this letter must be received prior to performing study related activities.  
 Role of the Sponsor  Representatives  
Sponsor representatives may provide support at the study site as required for the study under supervision of the Principal Investigator, including:  
• Provide study training relevant and pertinent to the involvement of personnel conducting 
study activities and investigator responsibilities  
• Technical support under the supervision of a study investigator, but no data entry, shall be performed by [CONTACT_230976]  
• Monitoring and auditing acti vities  
In addition, for this study, sponsor representatives may be authorized by [CONTACT_458] [INVESTIGATOR_634801]:  
• Support study investigators in performing the study procedure  
• Support data collection d uring the  procedure  
9. Selection of Subjects  
 Study Population  
Up to 30 healthy, non -smoking (or has refrained from smoking for 2 days) subjects,  ages [ADDRESS_847785] been met . 
Subjects who give informed consent for the protocol in order to  undergo screening for eligibility are not 
considered enrolled and should not be enrolled u ntil the screening is completed  as indicated in Sections 
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 30 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  8.3, 8.4, and 9, and they  are determined to meet all eligibility criteria. Study enrollment is accomplished  
by [CONTACT_634828] /exclusion criteria and 
health screening evaluation. Subject s who sign informed consent , but are not enrolled, are considered 
screen failure s. 
 Inclusion Criteria  
1. Healthy (ASA physical status 1), male or female subjects between the ages of 18 to 60 years;  
2. Completion of a health screening for a medical history by a licensed physician, nurse 
practitioner or physician assistant; 
3. Vital signs must be within the following ranges to be included: Vital sig ns measured sitting 
after [ADDRESS_847786]; heart rate: 45-90 bpm; systolic blood pressure: 110-140; diastolic blood 
pressure: 50-90. Out-of -range vital signs may be repeated once. [Pre -dose vital signs will be 
assessed by [CONTACT_079] [INVESTIGATOR_634802] (e.g., a medically qualified sub-investigator) 
before study drug administration. The Principal Investigator [INVESTIGATOR_634803]]; 
 Exclusion Criteria  
1. Has severe contact [CONTACT_230954] a reaction to standard adhesive materials found 
in pulse oximetry sensors, ECG electrodes, respi[INVESTIGATOR_230882], or other medical sensors [self -reported];   
2. Known neurological disorder (e.g., epi[INVESTIGATOR_002], the presence of a brain tumor, a history of brain 
surgery, hydrocephalic disorders, depression needing treatment with anti -depressive drugs, 
a history of brain trauma) [self-reported and assessment by [CONTACT_976] [INVESTIGATOR_9232]];  
3. Known cardiovascular disease (e.g., hypertension, coronary artery disease, prior acute 
myoca rdial infarction, any valvular and/or myocardial disease involving a decrease in 
ejection fraction, arrhythmias, which are either symptomatic or require continuous 
medication/ pacemaker/ automatic internal cardioverter defibrillator) , current implanted 
pacemaker or automatic internal cardioverter defibrillator  [self-reported and assessment by 
[CONTACT_976] [INVESTIGATOR_9232]];  
4. Has a clinically significant abnormal finding on medical history, physical examination, clinical 
laboratory tests, or ECG at the screening [self -repor ted and assessment by [CONTACT_976] [INVESTIGATOR_9232]];  
5. Recent use of psychoactive medication (e.g., benzodiazepi[INVESTIGATOR_1651], antiepi[INVESTIGATOR_006], Parkinson medication, anti -depressant drugs, opi[INVESTIGATOR_2438]) [self -reported and assessment by [CONTACT_976] [INVESTIGATOR_9232]];   
6. Subjects with known gastric diseases [self -reported and assessment by [CONTACT_976] [INVESTIGATOR_9232]];   
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.[ADDRESS_847787] [POC testing];  
8. Known history of allergic or adverse response to drugs to be administered [self -reported];   
9. Know n history of complications relating to previous general anesthesia or conscious sedation 
[self-reported and assessment by [CONTACT_976] [INVESTIGATOR_9232]];   
10. Known history of malignant hyperthermia [self -reported and assessment by [CONTACT_976] [INVESTIGATOR_9232]];   
11. Has a room air saturation  less than 95% by [CONTACT_406] [measurement by [CONTACT_976] [INVESTIGATOR_9232]];  
12. Has a clinically significant abnormal ECG [assessment by [CONTACT_976] [INVESTIGATOR_9232]];  
13. Has a clinically significant abnormal pulmonary function test via spi[INVESTIGATOR_038] [assessment by [CONTACT_976] 
[INVESTIGATOR_9232]];  
14. Pregnan t or lactating women [assessed by [CONTACT_230955] -reported];   
15. Subjects with tattooed skin specific to the sensor placement areas (forehead, fingers, chest) 
[self-reported and assessment by [CONTACT_976] [INVESTIGATOR_9232]];   
16. The subject must not take any prescription medication, except female hormonal contraceptives or hormone replacement therapy, from 14 days before the dosing until the end-of -study visit without evaluation and approval by [CONTACT_737]. Subjects who 
participated in a previous clinical trial who rece ived a required FDA approved concomitant 
medication, for example, naltrexone, but were not randomized may be considered for participation in this study if they meet the washout requirement [assessment by [CONTACT_976] [INVESTIGATOR_42550]]; 
10. Study Procedures  
 Schedule of Event s 
The Schedule of Events, Table 2 , summarizes the intervals and data collection procedures.  
Table 2: Schedule of Events  
Study Tasks  Pre-
screening  Enrollment  Execution  
 
No visit  Visit [ADDRESS_847788] (Female)   x x     
Complete blood count   x      
Inclusion/exclusion assessment   x x     
Vital monitoring   x x x  x  
Concomitant Medication   x x     
Urine drug screen and alcohol 
breathalyzer    x     
Safety Monitoring     x  x  
Sensor application     x  x  
Propofol or Propofol with 
Remifentanil administration      x  x  
BIS™, MOAA/S, TES assessments     x  x  
        
Safety Assessments and Compensation  
Adverse Event Assessment [ADDRESS_847789] be obtained prior to  any study -specific evaluations; for more details, refer to  Section 
9.2 
  
3. All Adverse Events, regardless of relatedness or outcome, will be collected and reported; for more details, refer to  
Sect
ion 11 
4. Device Deficiency will be collected and reported; for more details, refer to  Section 11. 
5. For more details regarding the subject compensation, refer to Section 15.6.  
 Pre-Screening  
Prior to the  Baseline/ Enrollment Visit , interested subjects will complete an online REDCap screening 
survey and have the opportunity to  review the Informed Consent Forms (ICFs). After the successful 

Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.[ADDRESS_847790] Consent  
At the enrollment visit, subjects will be approached to obtain written informed consent prior to any data  
collection. Once the Informed Consent Form ( ICF) is collected, the screening of the subject will follow. The 
purpose of the study and the benefits and risks of the procedures will be explained to the subject , and the 
consent process must be documented. Subjects who agree to study participation must sign IRB - approved 
ICF. Consent to participate in this study must be given in writing. Subjects that are unable to give consent 
will not be included in the study.  
 
The Investigator or designee must obtain written informed consent before any clinical study related 
activity takes place. Prior to entry into the study, the IRB and Medtronic-approved ICF form, and the 
Health Insurance Portability and Accountability Act (HIPAA) Authorization Form (if not included within the 
ICF) (the US only) will be given to each subject.  
 
The Investigator or designee will fully inform the subject of all aspects of the clinical study that are relevant 
to the subject’s decision to participate in the clinical study (e.g. , purpose and duration of the study, 
requirements of the subject during the study, potential risks and possible benefits associated with 
participation in this study). All items addressed in th e ICF must be explained. The language used shall be 
as non -technical as possible and must be understandable to the subjects. The subject must have ample 
time and opportunity to read and understand the ICF, to inquire about the details of the clinical study , 
and to decide whether or not to participate in the clinical study. All questions about the clinical study 
should be answered to the satisfaction of the subject. In the case that a subject is unable to read, an 
impartial witness must also be present and sign the informed consent to confirm that the research has 
been clearly explained and all of the subject’s questions have been answered.  
 
Neither the Investigator nor the investigation site staff shall coerce or unduly influence a subject to 
participate or  to continue to participate in the clinical study. The informed consent process shall not waive 
or appear to waive the subject’s rights. When the subject decides to participate in the clinical study, the 
HIPAA Form (if applicable) and the ICF  must be perso nally signed and dated by [CONTACT_423].  
 
After the subject ha s signed and dated the ICF , the Investigator must provide the subject with a copy.  
 Medtronic will inform the Investigators whenever information becomes available that may be relevant to  
the sub ject’s confirmed participation in the clinical study. The Investigator or his/her authorized designee  
should inform the subject in a timely manner.  
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.[ADDRESS_847791]’s confirmed participation in the clinical study. The revised information will be sent to the 
Investigator for approval by [CONTACT_1201]. After approval by [CONTACT_1201], a copy of this  information must be provided 
to the participating subjects, and the informed consent process , as described above, needs to be repeated.  
 Baseline/ Enrollment - Visit 1  
After successful completion of the pre- screening, qualified subjects will be invited to attend Visit 1 to 
complete the ICF. The Investigator or designee will inform the prospective subjects on the study procedures and explain the consenting process. Once ICF is signed, the  following will be performed during 
the screening:  
• Demographics ( race , ethn icity, sex, height, weight, skin tone, calculated body mass index 
(BMI) ) will be recorded on the eCRFs ;  
• Medical History will be evaluated and documented to evaluate for prior or existing medical 
conditions and/or procedures that would exclude subjects from participation in the study ; 
• Physical examination including an evaluation of general appearance, cardiovascular, 
respi[INVESTIGATOR_230907], skin, neurologic function, and head, eyes, ears, nose , and 
throat;  The American Society of Anesthesiologist (ASA) physical status classification system is 
used to evaluate the degree of a patient's "sickness" or "physical state.” Only subjects with 
ASA Physical status 1 will be enrolled ; 
• Concomitant Medications , includin g the history  of prescription and over the counter 
medication , will be carefully noted and recorded. Medication name, indication for use, dose, 
frequency, route of administration start/stop date  will be recorded on the eCRFs ; 
• Vital signs - Heart Rate, Systolic, and Diastolic Blood Pressures, Respi[INVESTIGATOR_230908] (SpO
2) will be evaluated  and recorded ;   
• Single 12 -lead ECG;   
• Complete blood count (CBC) ; 
• Urinary pregnancy test; 
• A urine sample will be tested for the presence of cotinine (nicot ine metabolite) to exclude 
smokers ; 
• Female subjects will have to attest to birth control methods ; 
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 35 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  • Adverse event review will be completed to assess events the baseline, and that occur after 
enrollment.   
The Baseline/ Enrollment  results will stay valid for 60 days .  
 Execution – Visit [ADDRESS_847792] will be instructed not to con sume beverages and foods containing 
alcohol, grapefruit, or caffeine/xanthine from [ADDRESS_847793].  
• Any significant change in health status since Visit 1 will be recorded.  
• Concomitant Medication  and adverse events will be checked . 
• All subjects will have urine drug screen and alcohol breathalyzer (Oral Ethanol) tests done.   
• Female subjects , childbearing age,  will also have a urine pregnancy test done.  
• Review Inclusion and Exclusion Criteria  based on additional information.  
• Enrollment is based upon successful inclusion /exclusion criteria during Visits 1 and 2.  
10.5.2.  Procedure – Visit 2  and Visit 3  
 
Figure 5 : Schematic Representation of Procedure Schedule   
 
The subjects  will receive two regimens of anesthesia with different drug combinations, with at least a [ADDRESS_847794]  will be 
sequentially assigned to start with either Propofol (P) or Propofo l with 4 ng/ml of Remifentanil (R) 
regimens , as shown in Figure 5 . 

Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 36 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  [IP_ADDRESS].  Safety Monitoring  
For the subject’s safety , an anesthesiologist authorized to administer sedation drugs will be responsible 
for administering any procedural drugs for the sedation and monitoring of subject safety and physical 
state. All other personnel involved with the safety monitoring of subjects must be trained in and familiar with the management of recovery of sedated patients. The study site should have a setting that is fully 
equipped for the monitoring and support of the respi[INVESTIGATOR_230899]. Subjects will be 
continuously monitored throughout the study. All subjects  will be monitored using an electrocardiogram  
(ECG), Pulse Oximeter for SpO
2, EtCO2. A clinician will be monitoring respi[INVESTIGATOR_634804]. The respi[INVESTIGATOR_634805], adequate oxygenation (SpO 2 >92%) , and CO [ADDRESS_847795] 
(with or without manually assisted breathing),  insertion of an airway device (oropharyngeal airway or 
laryngeal mask airway) and/or  intermittent positive pressure ventilation (IPPV). Mask or nasal cannula will 
be used for s upplemental O [ADDRESS_847796]’s safety. For patient safety, modifications to 
the procedure steps will be left to the judgment of the Principal Investigator .  
[IP_ADDRESS].  Regimen Set-Up  
The propofol and remifentanil will be administered using the Total Intravenous Anesthesia (TIVA) method 
via the target -controlled infusion (TCI) computer -controlled program, e.g., TIVA Trainer, or another 
computer -controlled program, to ensure that the targeted effect -site concentration of a drug is reached 
and maintained at each drug co ncentration  plateau. 1 % propofol  and remifentanil  diluted to a single 
concentration of 50 µg/ml will be used for this study. The i nfusion rate between 0 and 1200 ml/hr will be 
used to achieve a targeted concentration of propofol  and remifentanil. For propo fol, the effect -site 
concentration for propofol will be predicted using Schn eider pharmacokinetics and pharmacodynamics 
(PK/PD) model  [45, 46] . For remife ntanil, Minto [47, 50]  PK/PD model will be used. The assisted ventilation 
of the subject with either  facema sk, LMA or intermittent positive pressure ventilation (IPPV) may be used.   
 
Subjects  will have an intravenous catheter inserted for fluid and drug administration. Blood pressure will 
be monitored using an automated blood pressure cuff. 
[IP_ADDRESS].  Sensor Application  
The BIS ™ sensor will be applied per its  IFU. Subjects  will have an intravenous catheter inserted for fluid 
and drug administration. The TES sensor will be applied per its IFU to the calf with a stimulation of 2mA, 
2Hz for 1-[ADDRESS_847797] for ~12 minut es before starting any regimen . 
 
MOAA/S  and Tetanic Electrical Stimulation (TES)  
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 37 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
   
At each steady -state step and after equilibration, the MOAA/S assessment  will be administered by [CONTACT_634829] . It is preferred that the same anesthesiologist performs the MOAA/S assessment for all 
subjects , refer to Appendix A . 
 Subjects will receive noxious electrical stimulation  using Tetanic Electrical Stimulation (TES)  once they 
achieve a MOAA/S score <2 . The  instructions for testing the sensor placement are listed above. The BIS ™ 
value  will be recorded, followed by [CONTACT_230967]/S assessment . Then, TES will be initiated following the  
Instructions for Use (IFU) for the XAVANT  STIMPOD™  NMS 410/450X device. The subject will receive one 
stimulation of 50mA , 50 Hz  for 5 seconds . Their response, suc h as withdrawal of the extremity, a facial 
grimace, or a verbal groan will be recorded. Approximately 2 minutes a fter this assessment,  the BIS™ 
value will be recorded.  
 
 
[IP_ADDRESS].  Propofol Group 
The initial target effect -site concentrations of propofol will be 0.5 µg/ml followed by [CONTACT_634830] -site concentrations of 1.5, 2, 2.5, 3, 4, 6, to a maximum of 8 µg/ml until a BIS ™ value 
of not lower than 30 is intentionally reached  or per Investigator’s discretion . The BIS ™ value should not 
intentionally be taken below 30.  The equilibration time for each targeted plateau will be at least 12 
minutes. The BIS ™ value  and MOAA/S score  will be assessed and recorded when  the patient is awake and 
at the different targeted propofol concentrations . Tetanic Electrical Stimulation (TES)  will be used 
following the MOAA/S assessment when the  subject  reach es a MOAA/S score of <2 . The BIS ™ value will 
be recorded  at the time of subject’s response and  approximately  2 minutes following the TES assessment . 
The propofol concentration will be decreased by [CONTACT_634831].  
[IP_ADDRESS].  Propofol with Remifentanil Group  
Where remifentanil is administered with propofol, approximately [ADDRESS_847798]-site targeted concentration of remifentanil of 4 ng/ml , remifentanil will be given by a 
continuous infusion. Approximately within [ADDRESS_847799] -site concentration of remifentanil of 4 ng/ml throughout the study .  
 
The initial target effect -site concentrations of propofol will be 0.5 µg/ml followed by [CONTACT_634830] -site concentrations of 1.5, 2, 2.5, 3, 4, 6, to a maximum of 8 µg/ml until a BIS ™ value 
of not lower than 30 is intentionally reached  or per Investigator’s discretion . The BIS ™ value should not 
intentionally be taken below 30. The equilibrati on time for each targeted plateau will be approximately 
12 minutes. The BIS ™ value  and MOAA/S sc ore will be assessed and recorded when  the patient is awake 

Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.[ADDRESS_847800] -site concentration of  propofol.  Tetanic Electrical Stimulation (TES)  will be used 
following the MOAA/S assessment when the  subject  reach es a MOAA/S score of < 2. The BIS ™ value will 
be recorded  at the time of subject’s response and  approximately 2 minutes following the TES assessment. 
The propofol concentration will be decreased by [CONTACT_634831].  
[IP_ADDRESS].  CRF Data Collection  
The start time of any drug infusion, target effect -site concentrations , infusion rate,  the start time of the 
assessment s including BIS™ value  prior to MOAA/S assessment, Tetanic Elec trical Stimulation (TES)  and 
the end time of assessment as well at the BIS™ value at the time of subject’s response and approximately 
2 minutes following the TES assessment  will be recorded in the electronic Case Report Forms (e CRFs ). Any 
adjustments to the infusion rate and time of adjustment will be recorded, and any changes to subject 
management during the procedure will be noted on the eCRFs . 
[IP_ADDRESS].  Raw  Device Data Collection  
The device data (raw signals), including Heart Rate,  Blood Pressure,  Respi[INVESTIGATOR_26452], EtCO 2, SpO 2, BIS™, 
TCI, if available, will be collected in real -time during the procedure. The BIS ™ data will be recorded with a 
USB memory stick connected to the monitor. Periodically, the raw  device  data will be transferred directly 
to the Medtronic secure server for data quality review and analysis.  The instructions on the secure data 
transfer will be provided by [CONTACT_13735].  
 Follow -up  
10.6.1.  Phone Call 
The site will attempt to contact  [CONTACT_634832] e within [ADDRESS_847801] the following questions:  
• Have you had any medical problems since your discharge from the clinical research unit?  
• Have you taken any medications (either prescribed or self-medicated) since discharge  from the 
clinical research unit?  
 Assessment of Efficacy  
Refer to Section 14.  
 Assessment of Safety  
For safety analyses, adverse events will be summarized using frequency counts and percentages , refer to 
Section 14. Descriptive statistics will be provided by [CONTACT_92920], severity , and relationship to study 
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 39 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  procedures and devices. Individual listings of adverse events, including event type, start date, duration, 
severity, and  device-relatedness, will be provided as appropriate. Adverse events occurring during the 
procedure or  48 hours after the procedure will be recorded. For AEs and AE reporting requirements , refer 
to Section 11. 
 Recording Data  
The study will utilize the electronic Case Report Forms ( eCRFs)  in a database provided by [CONTACT_1034] .  
eCRF completion may be delegated by [CONTACT_39725] l Investigator (documented on the Delegated Task List) 
to other study personnel , but the Principal Investigator [INVESTIGATOR_634806]. The Principal Investigator [INVESTIGATOR_230924] -Investigator is req uired to 
approve all data on eCRFs via electronic signature.  
 
Additional details regarding procedures used for data review, database cleaning, issuing and resolving 
data queries, and identification of steps for creation, modification, maintenance, archiving retrieval or 
transmission of source data via any computerized systems will be provided in the study -specific Data 
Management Plan (DMP).  
 
 Role of Sponsor’s R epresentatives  
The s ponsor’s representatives will provide support as required for the clinical study, including but not 
limited to technical support during the procedure and/or technical support during follow-up in order to ensure that all study requirements are met, and the procedure is performed according to the Instructions 
for Use. The sponsor’s representatives providing technical support may be listed on the sponsor ’s 
technical support list.  
 Deviation Handling 
The investigator is required to conduct this study in accordance with the protocol, Good Clinical Practice 
(GCP), Institutional Review Board ( IRB) requirements, and applicable regulations . The investigator is not 
allowed to deviate from the above-mentioned documents except under emergency circumstances to 
protect the rights, safety , and well -being of human subjects.  
 
A study deviation is defined as an event when the investigator or site personnel did not conduct the study 
according to the protocol or the clinical trial agreement.  
 
The investigator is required to obtain prior approval from the sponsor and IRB before  initiating deviations 
from the Clinical Investigation Plan , except where necessary to protect the life or  safety and  physical well-
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.[ADDRESS_847802] to:  
• Patient informed consent procedure; 
• Patient eligibility criteria ; 
• Study data collection and reporting  (e.g., missing raw BIS data) ; 
• Serious Adverse Event /Serious Adverse Device Effect /Unanticipated Adverse Device Effect ( for 
reporting  refer to  Section 12). 
 
Deviations will be recorded at the site and reported to Medtronic on the eCRF. The deviation document 
shall be signed and dated by [CONTACT_230982]. At a minimum, the following 
information will be recorded:  
• identification of the investigator and site 
• description of deviation  
• date of occurrence  
• reason for the deviation  
• patient identifier, if associated with the event  
 
Deviations will be entered into a database to allow a comprehensive review on a regular basis for identifying  trends that warrant additional preventive or corrective actions to mitigate further occurrence. 
Clinical study management at Medtronic shall conduct this review.  Repetitive or serious investigator  
compliance issues may result in the need to initiate a corrective action plan, and in some cases, freeze  
enrollment or ultimately terminate t he investigator’s participation in the clinical study . 
 Study deviations must be reported to Medtronic, regardless of whether medically justifiable, pre -
approved by [CONTACT_230983] (see contact [CONTACT_230984]) or taken to protect the subject in an emerge ncy.  
 In the case that the deviation involves a failure to obtain a subject’s informed consent or is made to 
protect the life or physical well-being of a subject in an emergency, the deviation must be reported to the 
IRB as well as the study leader as soon as possible after the occurrence of the event. Reporting of all other study deviations should comply with IRB policies and/or local laws.  
 The investigator shall adhere to IRB requirements and procedures for reporting study deviations. 
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.[ADDRESS_847803]’s right to withdraw from the study at any time and for any reason without sanction, 
penalty or loss of benefits to which the subject is otherwis e entitled, and without jeopardizing their future 
medical care. The investigator may withdraw the subject at any time to protect the health, safety , or 
welfare of the subject. Every effort should be made to collect the status of any ongoing adverse events,  
at a minimum. All subjects will be encouraged to remain in the study through the follow -up phone call .  
 If the subject discontinues participating in the study prior to completing the study requirements, the reason for withdrawal will be recorded in the subject’s study records  and eCRF. 
 If withdrawal from the study is due to problems related to the investigational device safety or 
performance, the investigator shall ask for the subject’s permission to follow his/her status outside the 
clinical study . 
10.12.1.  Subject Exit From Study  
There are many scenarios in which a subject may exit the study. The f ollowing terms are used for 
withdrawal and completion:  
• Screen Failure: Did not meet the study inclusion/ exclusion criteria ;  
• Study Withdrawal:  Removal from the st udy after Enrollment by e ither subject, PI, or Sponsor, or 
technical problems ;  
• Study Complete: Completion of all study related activity by [CONTACT_423] ; 
• Lost to Follow up: Subjects lost to follow -up will be documented. The investigator should make 
every attempt to contact [CONTACT_42580] -up phone call within 
48 hours or to deter mine the occurrence/resolution of adverse events (if any).   
11. Risks and Benefits  
 Potential Risks  
Risks to participation are primarily physical. There are no social, economic, legal, long -term psychological , 
or other risks that have been identified. Risks under this protocol relate to both study devices and study procedures. We believe that the risks from the device(s) are in ke epi[INVESTIGATOR_42556] -
significant risk devices (NSR ). Further , the devices  in this study are non-invasive , and t he clinical protocol 
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.[ADDRESS_847804] detailing potential risks from study devices and the clinical protocol.   
11.1.1.  BIS™ Sensor Risks  
The BIS ™ Sensor is applied directly to the patient’s skin to enable recordings of electrophysiological (such 
as EEG) signals. The senso r will be used as per IFU. The sensors used in this study may expose subject s to 
the following risks:  
• Minor discomfort , allergic reaction, or skin irritation ( such as redness, itching) at the sensor 
application site is probable but is usually self -limited within hours.  
• Pressure points/ injury in application areas are possible but anticipated to be rare due to the short 
duration of the study. Care in the application and removal of the sensors is advised. Skin reactions 
will be observed during and after the  study procedures.  
• Electric shock is very rare, and the product design and testing ensure insulation and ground fault 
detection. No liquids should be used near the devices.  
• Burn to the skin (due to a small amount of heat generated) is a rare unanticipated risk, and not likely due to the short duration of the study .  
 Some Sensor Warnings and Cautions are listed below, for more information on warnings and cautions, 
refer to Sensor IFU.  
Warnings:  
• To reduce the hazard of burns during use of brain -stimulating devices (e.g., transcranial 
electrical motor evoked potential), place stimulating electrodes as far as possible from the bis 
sensor and place sensor according to instructions.  
Cautions:  
• Patient position may increase the risk of skin irritation on the forehead. With patients in prone position, consider minimizing pressure on the sensor. 
• Do not use if sensor is dry.  
• To avoid dry out, do not open pack until ready for use.  
• Due to intimate skin contact, reuse may pose risk of infection.  
• If skin rash or other unusual symptoms develop, stop use and remove.  
• Limited to short -term use (maximum 24 hours).  
• Do not cut sensor, as this will result in improper operation.  
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 43 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  • Upon removal, slight redness of skin may occur and typi[INVESTIGATOR_36065]  a short period of 
time. 
11.1.2.  BIS™ Monitoring System  Risks  
BIS™ Monitoring System  will be used per IFU . Some w arnings  are listed below, for more information on 
warnings and cautions refer to IFU.  
 
Warnings:  
• Explosion hazard: do not use the BIS™ complete system in a flammable atmosphere or where 
concentrations of flammable anesthetics may occur.  
• Monitor is not designed for use in MRI environment.  
• Use only the power cord supplied by [CONTACT_3455]. Never adapt the plug from the monitor to fit a non -standard outlet.  
• U.S.A. requirement: for proper grounding, the power receptacle must be a three-wire grounded outlet. A hospi[INVESTIGATOR_230925]. Never adapt the three -prong plug from the monitor to 
fit a two -slot outlet. If the outlet has only two slots,  make sure that it is replaced with a three -slot 
grounded outlet before attempting to operate the monitor.  
• If the integrity of the external protective earth ground is in doubt, the BIS™ complete system shall 
be operated from its internal battery power source only.  
• Be sure the monitor is mounted securely in place to avoid personal or patient injury.  
• The BIS™ complete monitor should not be used adjacent to or stacked with other equipment. If adjacent or stacked use is necessary, the BIS™ complete monitor should be observed to verify normal operation in the configuration in which it will be used.  
• When connecting external equipment (e.g., data capture computer), the system leakage current must be checked and must be less than the IEC [ZIP_CODE] -1-1 limit.  
• Using accessories other than those specified may result in increased electromagnetic emissions 
or decreased electromagnetic immunity of the BIS™ complete monitoring System.  
• The use of accessory equipment not complying with the equivalent safety requirements of this 
equipment may lead to a reduced level of safety of the resulting system. Consideration relating 
to the choice shall include: Use of the accessory in the patient vicinity. Evidence that the safety certification of the accessory has been performed in ac cordance to the appropriate IEC [ZIP_CODE]-1 
and/or IEC [ZIP_CODE]-1-[ADDRESS_847805].  
• Due to elevated surface temperature, do not place the BISX™ unit in prolonged direct contact [CONTACT_10974]’s skin, as it may cause discomfort.  
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 44 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  • The conductive parts of electrodes or sensor and connectors should not contact [CONTACT_230988], including earth.  
• To reduce the hazard of burns during use of high -frequency surgical equipment, the sensor or 
electrodes should not be located between the surgical site and the electro -surgical unit return 
electrode.  
• To reduce the hazard of burns during use of brain -stimu lating devices (e.g., transcranial electrical 
motor evoked potential), place stimulating electrodes as far as possible from the BIS™ sensor and 
make certain that sensor is placed according to package instructions. The sensor must not be 
located between def ibrillator pads when a defibrillator is used on a patient connected to the BIS™ 
complete system.  
• To minimize the risk of patient strangulation, the patient interface cable (PIC) must be carefully placed and secured.  
• Shock Hazard: Do not attempt to discon nect the power cord with wet hands. Make certain that 
your hands are clean and dry before touching the power cord.  
• Universal precautions shall be observed to prevent contact [CONTACT_230992]. Place contaminated material s in regulated waste container.  
• Do not mix disinfecting solutions (e.g., bleach and ammonia), as hazardous gases may result.  
• Electrical Shock Hazard: Do not remove monitor covers during operation or while power is connected to monitor.  
• Electrical Shock Hazard: The manufacturer ’s inspection of this apparatus verified that the ground 
leakage current and the patient safety current were less than the specified limits established by [CONTACT_230990]. As a matter of safe practice, the institutio n should conduct 
periodic tests to verify these currents.  
• Whenever an event such as spi[INVESTIGATOR_230926], re -test ground leakage current 
before further use.  
• Leakage current must be checked by a qualified biomedical engineering technician  whenever 
instrument case is opened.  
• Power supply is internally fused. Replace power supply only with Covidien BIS ™ Complete power 
supply.  
• Portable RF communications equipment (including peripherals such as antenna cables and 
external antennas) should be used no closer than 30 cm (12 inches) to any part of the BIS™ 
complete monitoring system, including cables specified by [CONTACT_3455]. Otherwise, 
degradation of the performance of this equipment could result.  
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 45 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  • Check Target Range alarm limits to ensure they are appropriate for the patient being monitored 
with each use. Ensure Target Range alarm limits do not exceed the standard thresholds set by [CONTACT_230991].  
• Do not decrease the adjustable alarm volume below ambient sound levels. Decreasing the alarm  
volume below ambient levels may compromise patient safety.  
• Explosion hazard: do not use the BIS™ complete system in a flammable atmosphere or where 
concentrations of flammable anesthetics may occur.  
• Use only the power cord supplied by [CONTACT_3455]. Never adapt the plug from the monitor to fit a non -standard outlet.  
• If the integrity of the external protective earth ground is in doubt, the BIS™ complete monitor 
shall be operated from its internal battery power source only.  
• Due to elevated surface tem perature, do not place BISX™ unit in prolonged direct contact [CONTACT_230987]’s skin, as it may cause discomfort.  
• The conductive parts of electrodes or sensor and connectors should not contact [CONTACT_230988], including earth.  
• To reduce the hazard of  burns during use of high -frequency surgical equipment, the sensor or 
electrodes should not be located between the surgical site and the electro -surgical unit return 
electrode.  
• The sensor must not be located between defibrillator pads when a defibrillator  is used on a 
patient connected to the BIS™ complete system.  
• Check Target Range alarm limits to ensure they are appropriate for the patient being monitored 
with each use. Ensure Target Range alarm limits do not exceed the standard thresholds set by [CONTACT_230991].  
• Universal precautions shall be observed to prevent contact [CONTACT_230989]. Contaminated materials should be disposed of in accordance with national and local waste disposal legislation and requirements.  
• Do not mix disinfecting solutions (e.g., bleach and ammonia) as hazardous gases may result.  
• Leakage current must be checked by a qualified biomedical engineering technician whenever an instrument case is opened.  
• A power supply is internally fused. Replace power supply only with Covidien BIS™ complete power 
supply.  
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 46 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  • Electrical Shock Hazard: The manufacturer’s inspection of this apparatus verified that the ground 
leakage current and the patient safety current were less than the specified limits established by  
[CONTACT_230990]. As a matter of safe practice, the institution should conduct periodic tests to verify these currents. Whenever an event such as spi[INVESTIGATOR_634807], re -test before further use.  
• Using accessories other than those specified may result in increased electromagnetic emissions 
or decreased electromagnetic immunity of the BIS™ complete monitoring system.  
The BIS™ complete system should not be used adjacent to or stacked with other equipment. If adjacent 
or stacked use is necessary, the BIS™ complete monitor should be observed to verify normal operation 
in the configuration in which it will be used.  
11.1.3.  Nellcor™ Pulse Oximeter  
• Pulse and Tissue Oximetry Sensor placement involves positioning pulse and tissue oximet ry 
sensors on the subject in the same manner that is used on hospi[INVESTIGATOR_26328]. 
• The sensors may be warm to the touch. Under normal operating conditions, (no fault conditions), 
the sensors are not expected to overheat. If the sensors are too warm, they will be removed 
immediately. 
• The sensors exert a minimal amount of pressure. Sensors may leave minor impressions at the 
sensor application site, which should fade and resolve within the day. They should not cause 
discomfort. If the sensors are too uncomfor table, they will be removed.  
• Adhesive sensors may cause some irritations to the skin in some subjects. Typi[INVESTIGATOR_634808], an allergic reaction can occur.  
• Removal of the sensor may cau se pulling of the skin or hair, and this can be felt as pain.  
• The risk in the use of oximetry sensors is believed to be minor.  
• A heating pad or hot water bottles may be used on the hands to improve circulation. The subject may experience some mild discomfo rt if the water is too warm. To minimize the discomfort, the 
subject will be asked if the heating is too warm, it will be turned on the lowest level possible for 
comfort, removed or additional separation will be used between the heater and the site for 
com fort.  
11.1.4.  XAVANT S TIMPOD ™ Quantitative NMT Monitor  Risks  
STIMPOD ™ Quantitative NMT monitor will be used per IFU. Some warnings are listed below, for more 
information on warnings and cautions refer to the IFU.  
Warnings:  
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 47 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  • Use of cables or accessories other than those supplied with the STIMPOD may result in serious 
injury . 
• Maintenance on this device may only be performed by [CONTACT_634833].  
• Do not use the STIMPOD in close proximity to equipment that produces st rong electromagnetic 
fields, such as high frequency surgical equipment. The cable leads could act as an antennae and dangerous currents could be induced as a result.  
• Do not apply the STIMPOD to patients with implanted electrical devices, such as cardiac pacemakers, without first consulting with an appropriate medical specialist.  
• The device should not be used adjacent to or stacked with other equipment and that if adjacent or stacked use is necessary, the device should be observed to verify normal operation in the configuration in which it will be used.  
• The patient should avoid contact [CONTACT_230994], produce an electrical conductive connection with other equipment and/or enable capacitive coupling.  
• The cables should be positioned in such a way that they do not contact [CONTACT_634834]. 
• Simultaneous connection of a patient to high frequency surgical ME equipment and the STIMPOD may result in burns and possible damage to the stimulator. 
• Operation in close proximity (e. g. 1m) to a shortwave or microwave therapy ME equipment may 
produce instability in the stimulator output.  
• Application of electrodes near the thorax may increase the risk of cardiac fibrillation.  
• No modification of the equipment is allowed.  
• Do not modify this equipment without authorization of the manufacturer.  
• If this equipment is modified, appropriate inspection and testing must be conducted to ensure continued safe use of the equipment.  
11.1.5.  General Anesthe sia Risks  
There are some risks associated with taking general anesthetics, but they are relatively safe when 
administered correctly . Although not all of these side effects may occur, if they do occur, they may need 
medical attention. All Subjects will be monitored by [CONTACT_634835] f or the effects.  The 
most common side effects of general anesthesia include sore throat due to the breathing tube, nausea, 
vomiting, dizziness,  bruising, or soreness from the IV drip, shivering and feeling cold, difficulty passing 
urine. These may occur despi[INVESTIGATOR_634809].  For additional information related to 
potential medication , risks refer to Table [ADDRESS_847806]’s  teeth. This risk increases if the subject has loose teeth or other dental problems. With any 
medication given, the Subject could have an allergic reaction. Although rare, unexpected severe 
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.[ADDRESS_847807] will be present to minimize all risks related to 
anesthesia. 
Table 3: Possible Side Effects using Medication  
Possible side effects using remifentanil  but not limited 
to 
• blurred vision  
• chest pain or discomfort  
• confusion  
• difficult or troubled breathing  
• dizziness, faintness, or lightheadedness when 
getting up suddenly from a lying or sitting 
position  
• irregular, fast or slow, or shallow breathing  
• lightheadedness, dizziness, or fainting  
• muscle stiffness or tightness  
• pale or blue lips, fingernails, or skin  
• shortness of breath  
• slow or irregular heartbeat  
• sweating  
• unusual  tiredness or weakness 
 
 Less common side effects of remifentanil  but not 
limited to  
• bluish lips or skin  
• chills  
• decrease in cardiac output  
• fast, pounding, or heartbeat or pulse  
• feeling of warmth  
• fever  
• headache  
• nausea or vomiting  
• nervousness  
• not breathing  
• pain after surgery  
• pain in the shoulders, arms, jaw, or neck  
• pounding in the ears  
• problems with bleeding or clotting  
• redness of the face, neck, arms, and 
occasionally, upper chest  
• shivering  
• allergic reactions 
• other side effects may occur  
Possible side effects using Propofol but not limited to  
• hypotension 
• apnea lasting 30 -60 sec  
• apnea lasting >60 sec  
• movement  
• injection site burning/stinging/pain  
• respi[INVESTIGATOR_634810] 
• arterial hypotension  
• anaphylaxis  
• asystole  
• bronchospasm  
• cardiac arrest  
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 49 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  • hypertriglyceridemia  
• hypertension  
• rash  
• pruritus  
• arrhythmia  
• bradycardia  
• cardiac output decreased concurrent 
opi[INVESTIGATOR_634811])  
• tachycardia  • seizures  
• opi[INVESTIGATOR_634812] r eaction 
• pancreatitis 
• pulmonary edema  
• phlebitis  
• thrombosis 
• renal tubular toxicity  
• allergic reactions 
• other side effects may occur  
 Potential Benefits  
There are no medical benefits to the subjects who participate in this study. There is, however, the 
potential for benefiting future su bjects should this study enable the development of improved medical 
monitoring devices.  
 Risk-Benefit Rationale  
Medtronic has determined that this is a study of a “non -significant risk device” due to the nature of the 
devices being tested. Utilizing the FDA criteria1,2 listed below to distinguish between significant and non -
significant risk devices, Medtronic has determined that:   
• The device under investigation is not intended as an implant and does not present a potential 
for serious risk to the health, safety, or welfare of a subject;  
• The device  under investigation is not purported or represented to be for use supporting or 
sustaining human life and does not p resent a potential for serious risk to the health, safety, 
or welfare of a subject;  
• The device under investigation  is not for a use of  substantial importance in diagnosing, curing, 
mitigating, or treating disease, or otherwise preventing impairment of human health, and 
does not present a potential for serious risk to the health, safety, or welfare of a subject; and 
• The device under investigation does not otherwise present a potential for serious risk to the health, safety, or welfare of a subject.  
 
1 21CFR812.2 (b)(1)(ii) and 21CFR812.3(m)  
2 Information Sheet Guidance For IRB/EC , Clinical Investigators, and Sponsor. Significant Risk and Non- significant Risk Medical Device Studies/  
January 2006/UMC126418  
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.[ADDRESS_847808] been assessed and are not greater than those of currently 
approved and marketed devices of the same type  (e.g., pulse and tissue oximeters, EtCO 2 monitors, non -
invasive blood pressure monitors, ECG or respi[INVESTIGATOR_230933]). Society may benefit from more accurate 
medical monitors. 
 Medtronic  requests that the reviewing IRB indicates  its agreement with this determination of non -
significant risk device in its letter of approval for this study.  
12. Adverse Event s and Device Deficiencies  
 Adverse Events  
AE (Adverse Event) definitions are provided in Table 4 . AE information will be collected throughout  the 
study from the BIS ™ sensor application until the f ollow-up phone call . A list of anticipated adverse events  
and risks  that are expected in nature is included in Section 10.  
 
Reporting of these events to Medtronic will occur on an AE Form. Each event must be reported separately. 
Documented pre-existing conditions are not considered AEs unless the nature or severity of the condition 
has worsened.  
 For AE s that require immediate reporting (see Table 4), initial reporting may be done by [CONTACT_648], fax, or on 
the eCRF completing as much information as possible. The completed AE eCRF must be submitted to 
Medtronic as soon as possible.   
 Any medication/treatment associated with the treatment of an AE must be reported  
 AE assessment for the purposes of this study will cease after the follow -up phone call within [ADDRESS_847809] possibly related to the study will be followed until 
resolved, stabilized, and/or returned to baseline. 
 
Table 4: Definition of Adverse Events and Device Deficiencies  
General  
Adverse Event (AE)  Any untoward medical occurrence, unintended disease or injury, or untoward clinical signs 
(including abnormal laboratory findings) in subjects, users or other persons, whether or not 
related to the investigational medical device. 
NOTE 1: This definition in cludes events related to the investigational medical device or the 
comparator.  
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 51 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  NOTE 2 : This definition includes events related to the procedures involved.  
NOTE 3: For users or other persons, this definition is restricted to events related to 
investigational medical devices.  
Adverse Device Effect (ADE)  Adverse event related to the use of an investigational medical device.  
NOTE 1: This definition includes adverse events resulting from insufficient or inadequate 
instructions for use, deployment, implantation, installation, or operation, or any malfunction 
of the investigational medical device. 
NOTE 2: This definition includes any event resulting from use  error or from intentional 
misuse of the investigational medi cal device.  
Device Deficiency (DD)  Inadequacy  of a medical device with respect to  its identity, quality, durability, reliability, 
safety or performance.  
NOTE: Device deficiencies include malfunctions, use errors, and inadequate labeling . 
Relatedness  
Device Related  An AE that results from the presence or performance (intended or otherwise) of the device.  
Procedure Related  An AE that occurs related to the procedure.  
Seriousness  
Serious Adverse Device 
Effect (SADE) Adverse device effect that has resulted in any of the consequences characteristic of a 
Serious Adverse Event . 
Serious Adverse Event (SAE)  An adverse event that  
a) led to death,  
b) led to serious deterioration in the health of the subject, that either resulted in  
1) a life -threatening illness or injury, or  
2) a permanent impairment of a body structure or a body function, or  
3) in-subject or prolonged hospi[INVESTIGATOR_059], or  
4) medical or surgical in tervention to prevent life- threatening illness or injury or 
permanent impairment to a body structure or a body function,  
c) led to fetal distress, fetal death or a congenital abnormality or birth defect.   
NOTE:  Planned hospi[INVESTIGATOR_272] a pre -existing condition, or a procedure required by [CONTACT_305556], without serious deterioration in health, is not considered a serious adverse event.  
Unanticipated Adverse 
Device Effect  (UADE)  Any serious adverse effect on health or safety or any life-threatening problem or death 
caused by, or associated with, a device, if that effect, problem, or death was not previously 
identified in nature, severity, or degree of incidence in the CIP or application (including a supplementary plan or application), or any other unanticipated serious problem associated 
with a device that relates to the rights, safety or welfare of subjects.  
Complication  An adverse event that includes the following is considered a complication:  
• Results in death,  
• Involves any termination of significant device function, or  
• Requires an invasive intervention  
 
Non -invasive (21 CFR 812.3 (k)): when applied to a diagnostic device or procedure, means 
one that does not by [CONTACT_180996]:  
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 52 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  • Penetrate or pi[INVESTIGATOR_180989], the ocular 
cavity, or the urethra, or  
• Enter the ear beyond the external auditory canal, the nose beyond the nares, 
the mouth beyond the pharynx, the anal canal beyond the rectum, or the 
vagina beyond the cervical os  
Where “penetrate” means: to pass, extend, pi[INVESTIGATOR_835], or diffuse into or through something; to enter by [CONTACT_354028]; to gain entrance to, and “pi[INVESTIGATOR_835]” 
means to force a way into or through something  
 
NOTE (FDA): Blood sampling that involves simple venipuncture is considered noninvasive, 
and the use of surplus samples of body fluids or tissues that are left over from samples taken 
for non -investigational purposes is also considered noninvasive.  
Observation  Any AE that is not a complication.  
 NOTE 1: Only system or procedure related A es will be classified as “Complication” or 
“Observation”  
 Reporting of Adverse Events   
Principal Investigator [INVESTIGATOR_634813].   
Study Contact [CONTACT_7171]:  
Clinical Affairs  Medical Affairs  
Stephanie Monza, BS, CCRC  
Senior Clinical Research Specialist/ Clinical 
Study Manager Medtronic  
[ADDRESS_847810]  
Carlsbad, CA [ZIP_CODE] 
 
 
12.2.1.  Adverse Event and Device Deficiency Classification  
All AE and DD will be reviewed by a Medtronic representative. AE s will be classified according to the 
definitions provided.  
Upon receipt of AE at Medtronic, a Medtronic representative will review the AE/DD for completeness and accuracy and when necessary will request clarification and/or additional information from the 
Investigator. Medtronic will utilize MedDRA for Regulatory Activities, to assign a MedDRA term for each 
AE based on the information provided by [CONTACT_093].  
Regulatory reporting of AEs and DDs will be completed according to local regulatory requirements. Refer 
to Table [ADDRESS_847811] regarding a UADE, [LOCATION_003]DE, SAE and/or SADE, contact a study representative 
immediately (refer to the study contact [CONTACT_230997]’s study documents binder/investigator site file or refer to the Sponsor contact [CONTACT_131484]).  
AEs and Deaths will be classified according to the standard definitions as outlined below: 
Table 5: Adverse Event Classification Responsibilities  
What is classified?  Who classifies?  Classification Parameters  
Relatedness  Investigator  Device, Procedure  
Sponsor  Device, Procedure, BIS™ System components  
Seriousness  Investigator  SAE, DD with SADE potential  
Sponsor  SAE, UADE/[LOCATION_003]DE, Complication or Observation (for all procedure related 
adverse events), DD with SADE potential  
Diagnosis  Investigator  Based on presenting signs and symptoms and other supporting data  
Sponsor  MedDRA term assigned based on the data provided by [CONTACT_10670]  
12.2.2.  Adverse Event and Device Deficiency Reporting Requirements  
Regulatory reporting of AEs and DDs will be recorded and reported according to local regulatory 
requirements. It is the responsibility of the Investigator and the sponsor to abide by [CONTACT_230998]’s IRB .  
Table 6: Reporting R equirements for Events  
Serious Adverse Device Effects (SADE), including Unanticipated Adverse Device Effect (UADE):  
Investigator submits to:   
Medtronic  Within [ADDRESS_847812] learns of the event . 
Regulatory Authority  As per local reporting requirements.  
IRB Submit to IRB per local reporting requirement.  
Sponsor submits to:   
Regulatory Authorities  Reporting timeframe as per local requirement.  
IRB Submit to IRB per local reporting requirement.  
Serious Adverse Events (SAE)  
Investigator submits to:   
Medtronic  Within [ADDRESS_847813] learns of the event . 
Regulatory Authority  As per local reporting requirements.  
IRB Submit to IRB per local reporting requirement.  
Sponsor submits to:   
Regulatory Authorities  Reporting timeframe as per local requirement.  
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 54 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  IRB Submit to IRB per local reporting requirement.  
Adverse Device Effects (ADE)  
Investigator submits to:   
Medtronic  Within [ADDRESS_847814] learns of the event . 
Sponsor submits to:   
Regulatory Authority  As per local reporting requirements.  
IRB  Submit to IRB per local reporting requirement.  
Sponsor submits to:   
Regulatory Authorities  Reporting timeframe as per local requirement  
IRB  Submit to IRB per local reporting requirement.  
All other A Es 
Investigator submits to:   
Medtronic  Submit as soon as possible, but no later than within [ADDRESS_847815] learns of the event . 
Regulatory Authority  As per local reporting.  
IRB  Submit to IRB per local reporting requirement.  
Device Deficiency with SADE potential  
Investigator submits to:   
Medtronic  No later than [ADDRESS_847816] learns of the event.  
Regulatory Authorities  As per local reporting requirements. 
IRB  As per local reporting requirement. 
Sponsor submits to:   
Regulatory Authorities  As per local reporting requirements. 
IRB  As per local reporting requirement. 
All other Device Deficiencies  
Investigator submits to   
Medtronic  No later than [ADDRESS_847817] learns of the event.  
Regulatory Authorities  As per local reporting requirements. 
IRB As per local reporting requirement. 
Sponsor submits to:   
Regulatory Authorities  As per local reporting requirements. 
IRB As per local reporting requirement. 
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.[ADDRESS_847818] Complaint: Any written, electronic or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, safety, effectiveness or performance of a medical device that has been placed on the market.  
• Abuse: Abnormal use (definition acc. #4.1 of Meddev 2.12 -1  
• Misuse: Use error (definition acc. #4.20 of Meddev 2.12 -1) 
 
It is the responsibility of the investigator to report all product complaint(s) associated with a medical 
device distributed by [CONTACT_13735], regardless whether they are related to intended use, misuse or abuse of the product. Reporting must be done immediately and via the regular channels for market -released 
products. The reporting of product complaints by [CONTACT_569848]. Medtro nic will notify the Ra s (e.g. CA) as applicable for the following 
incidents immediately upon learning of them and is not limited to AE s and DDs only:  
• Any malfunction or deterioration in the characteristics and/or performance of a device, 
as well as any inadequacy in the labeling or instructions for use which led or might have led to the death or serious deterioration in the state of health of a patient, user, or other person. 
• Any technical or medical reason resulting in withdrawal of a device from the market by [CONTACT_3455].  
• Any serious deterioration in the state of health, including:  
 Life-threatening illness or injury  
 Permanent impairment of a body function or permanent damage to a body structure  
 A condition necessitating medical or surgical interventio n to prevent permanent 
impairment of a body function or permanent damage to a body structure  
13. Data Review Committees  
A Data Monitoring Committee (DMC) , Adverse Events Advisory Committee (AEAC) will not be  utilized for 
this clinical study as there are no safety concerns suggesting  the need for a DMC. This study  is considered 
a non-significant risk for study participants . Thus , the need for additional safety oversight beyond 
Medtronic’s already rigorous safety monito ring processes is not required. A Medtronic Medical Advisor , 
as needed, will provide an independent medical review according to the study Safety and C omplaint  
Management Plan. The Medical Advisor will not be affiliated with an investigative center.  
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.[ADDRESS_847819] ical Design and Methods  
Statistical analyses will be conducted  by [CONTACT_634836] (SAP .) Any changes in statistical methods will be detailed in the Clinical Study Report (CSR.) Data 
exclusion will be c aptured in the Data Management Plan.    
 Sample Size Justification  
Up to [ADDRESS_847820] dropouts. Based on the dose-response relationship (logistic model)  
with an allowable error of ± 15% for BIS 50 and a coefficient of variation of 25% at the alpha level of 0.05, 
the sample size will provide sufficient power (>80%) to evaluate the performance of anesthetic agents.   
 Analysis Populations  
The primary effectiveness analysis will be  based  on all evaluable data from this study. Subjects who 
discontinue participation prematurely will be included in the analysis of results. Subjects who withdraw 
from the stud y prior to completing both regimens will be replaced by a new subject . 
 Statistical Methods 
Standard demographic information and baseline characteristics will be summarized using descriptive statistics. For safety assessments, adverse events ( AEs) will be summarized using frequency counts and 
percentages. Descriptive statistics will be provided by [CONTACT_231001] .  
 Any subject who responds to any verbal command with MOAA/S assessment score of  2, 3, 4, and 5 will 
be considered as responsive. Subjects with MOAA/S assessment score s of <2 will be considered 
unresponsive. Tetanic Electrical Stimulation (TES)  will be employed  with an MOAA/S assessment score of  
<2.  
 
The BIS ™ index value collected from the left side of the brain will be used for primary analysis to reflect 
the typi[INVESTIGATOR_230934]. The BIS ™ index value collected from the right side of 
the brain will be used for internal research purposes.  
 The value of BIS™ wil l be assessed at the different targeted- controlled drug concentrations or infusion 
rates . The logistic model (simplified Sigmoid E
max model ) will be used to analyze the relationship between 
the BIS™ index and loss of responsiveness through the probability of response curves. The v alues of BIS™, 
at which 50% (BIS 50) and 9 5% (BIS 95) of subjects are unresponsive , and their 95% confidential intervals will 
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 57 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  be derived.  The systematic variance between group s will be evaluated. The Prediction Probability score 
(Pk) for correctly predicting if the subject was responsive or unresponsive will be assessed.   
15. Ethics  
 Statement(s) of Compliance  
The investigator is responsible for ensuring that the clinical study is  conducted  in accordance with : 
• This C linical Investigational Plan and Standard Operating Procedures (SOPs). 
• Food and Drug Administration (FDA) Good Clinical Practice (GCP) guidelines and regulatory 
requirement(s), including 21  CFR 803, 21 CFR 812.2 , 21 CFR 50, 21 CFR 56. FDA Financial Disclosure 
regulations, as well as the International Conference on Harmonization (ICH) guidelines and any 
other regional/national requirements for clinical trials, as applicable.  
• If the IRB or other  regulatory authority imposes any additional requirements (e.g., safety reports, 
progress reports , etc.), Medtronic will prepare the required documents and send them to the 
respective authority.  
• Investigators must inform Medtronic of any change in the status of IRB approval once the 
investigation site has started enrollment. If any action is taken by [CONTACT_634837], that information will be forwarded to Medtronic by [CONTACT_231005]. 
• The clinical study will not begin until the IRB approval / notification is received. Written IRB 
approval and any conditions of approval imposed by [CONTACT_634838]. 
16. Study Administration 
 Monitoring  
Site monitoring visits will be performed by [CONTACT_634839] s taff per the 
monitoring plan  to ensure:  
a) Overall compliance with the protocol, GCP, and the applicable regulations.  
b) Accurate records are being maintained.  
c) Accurate and complete study data are being reported (comparing CRF to source 
documents.) In some cases, the CRF will also be the source documentation of some 
information.  
d) Informed consent has been obtained for all study subjects.  
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 58 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  e) Adverse events and protocol deviations are documented and reported.  
f) Investigational and non -investigational device accounta bility and disposition are 
accurately documented.  
Monitoring visits will be conducted at the start, during, and at the closure of the clinical study in 
accordance with Medtronic SOPs and the Monitoring Plan. An interim monitoring visit may be combined  
with the closing monitoring visit. Monitoring may be performed with in -person visits or remotely, when 
applicable. The quality of the device data obtained from the investigator and maintained by [CONTACT_634840]. Prior to any device data quality checks, the 
ICF will be checked in person or remotely.  
 
The f requency of monitoring visits will occur based on subject enrollment, duration of the study, study 
compliance, site performance, site adherence to the protocol, findings from previous monitoring visits, 
and any suspected inconsistency in data that requires inv estigation. The monitoring visit frequency may 
be changed based on study needs and subject enrollment rates . Specific monitoring requirements are 
detailed in the study -specific Monitoring Plan.  
 
The Sponsor will provide updated contact [CONTACT_142821], including the monitors’ name [CONTACT_3669] [CONTACT_231008].  
 Medtronic or designee will conduct site monitoring visits to monitor compliance with the protocol, clinical 
study agreement, and applicable regulations, and  adherence to the data collection procedures, to assess 
the accuracy and completeness of  submitted clinical data, and to verify that records are being properly 
maintained for  the duration of the study . 
 Monitoring activities will be documented and include a summary of what the m onitor reviewed and the 
observations regarding the completion of previous action items, significant findings, facts, deviations, 
conclusions, and recommended actions to be taken to secure compliance.  
 
If problems are encountered with the quality of the co llected data , the study may  be halted for the period 
of time  until the problem has been assessed and corrected . The evaluation of the data quality will be the 
responsibility of the Medtronic Clinical Affairs personnel or designee.  
 
The Investigator or authorized study personnel should  be available at each monitoring visit. Direct a ccess 
to the subject records and other source data must be provided to study eCRF, the Sponsor, regulatory 
authorities, auditors, IRB members , or inspectors.  
 
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.[ADDRESS_847821] be consistent with the source documents , and discrepancies need to be justified in a documented 
rationale, signed and dated by [CONTACT_941] (principal) investigator, and filed in the patient medical file.  
 
Only authorized persons can complete eCRFs. All data requested on the e CRF are considered required. 
The Principal Investigator [INVESTIGATOR_230935]/her signature [CONTACT_634847] e CRFs. The Investigator’s electronic  signature [CONTACT_231035]. Changes to data  previously submitted to 
the sponsor will require a new electronic signature [CONTACT_3265] [CONTACT_634841]/approve the 
changes.  
 
Medtronic will only consider eCRFs to be complete when all discrepancies have been resolved by [CONTACT_634842]. Also , specific eCRFs must be reviewed and  electronically signed 
by [CONTACT_737], indicating his/her agreement with the accuracy of all recorded  data. It is expected 
that the Investigator and his/her staff will cooperate with the monitoring team and  provide any missing 
data in a timely manner.  
 
The Electronic Data Capture (EDC) system maintains an audit trail on entries, changes, or corrections in 
eCRFs. Upon completion of a n eCRF, the investigator shall sign the e CRF in a timely manner , if a change 
to an already signed eCRF occurs, the investigator shall re -sign this eCRF. 
16.2.2.  Device Data  
The raw data will be collected using BIS ™ and other equipment, e.g., co -oximeter, blood pressure 
monitors , etc. The data will be exported to an encrypted flash memory  device for each subject.  The 
memory device will be stored at the investigation site. Periodically, the raw data will be transferred 
directly to the Medtronic secure server for data quality review  and analy sis. 
16.2.3.  Direct Access to Source Data/Documents 
Data entered must be traceable to source documents. Source documentation is defined as the first -time  
data appear and may include original documents, data , and records (e.g., hospi[INVESTIGATOR_1097], clinical and 
office  charts, procedure reports, laboratory records , or evaluation checklists, recorded data from 
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.[ADDRESS_847822] files .) 
 The eC RFs (or paper copi[INVESTIGATOR_014]) may not serve as source documents. Source documentation for data elements 
not routinely captured in medical records may vary from site to site; the site may use source document worksheets if identified as source documents and are signed and dated appropriately.  
16.2.4.  Time Windows for Completion of eCRFs  
eCRFs are recommended to be entered into the RDC system within [ADDRESS_847823], or comment  on the data.  
 Visual and/or computer data review will be performed to identify possible data discrepancies. Manual  
and/or automat ed queries will be created in the Oracle remote data capture (RDC) system and will be  
issued to the site for an appropriate response. The site staff will be responsible for resolving all queries in  
the database in a timely manner and as requested by [CONTACT_13735].  
 
Automatic discrepancies will be issued in accordance with the Edit Check Document and the eCRF 
Database Question Specifications.  
In the event of data discrepancies, investigational centers will be asked to resolve queries electronically  
in the RDC system; otherwise, irresolvable dat a-related issues will be routed to the Sponsor for review 
and final disposition. 
 Confidentiality  
All information and data sent to parties involved in study conduct concerning subjects or their participation in this study will be considered confidential. Study sites will assign a unique SID to each 
subject. Records of the subject/SID relationship will be maintained by [CONTACT_3452]. The SID number is to 
be recorded on all study documents to link them to the subject’s medical records at the study site.  
Confidentiality of data will be observed by [CONTACT_569851]. All data shall be secured against unauthorized access. The privacy of each subject and 
confidentiality of his/her information shall be preserved in reports and when publishing any data.  In the 
US, “Protected Health Information” (PHI) will be maintained in compliance with the HIPAA of 1996. To 
maintain confidentiality, the subject’s name [CONTACT_634848]19049SONORA Version  5.[ADDRESS_847824]’s name/PHI is 
included for any reason, it will be blinded as applicable. In the event of inability to blind the identification 
(e.g., digital media), it will be handled in a confidential manner by [CONTACT_92999].  Data relating 
to the study might be made available to third parties (for example in case of an audit performed by [CONTACT_14687]), 
provided the data are treated as confidential and that the subject’s privacy is guaranteed. No identifiable 
subject information will be published.  
 Audits and Investigation Site Inspections  
In addition to regular monitoring visits, Medtronic may conduct audits at participating investigation sites.  
The purpose of an audit is to verify the adequate performance of the clinical study related activities. Regulatory authorities may also perform  inspections at participating investigation sites. Any regulatory 
authority inspection announcements shall  be forwarded immediately to the Medtronic per contact 
[CONTACT_85830]. 
 
The investigator and/or  institution shall permit Medtronic and regulatory bodies direct access to source 
data and documents, taking into account any restrictions due to local law, to perform clinical study related 
monitoring, audits, IRB  review (if applicable), and regulatory inspections.  
 Subject Compensation  
The study will incur no cost to the subject.  The subject  will be paid  $500 in total compensation, $[ADDRESS_847825] regimen, and an additional $300 for completing the second 
regimen. Screen failures will be compensated $25.   
 Liability  
Medtronic maintains appropriate clinical study liability insurance coverage as required under applicable laws and regulations and will comply with applicable local law and custom concerning specific insurance 
coverage. If required, a clinical study insurance statement/certificate will be provided to the IRB . 
 CIP Amendments  
The investigator may propose any appropriate modification(s) to the Clinical Investigation Plan or investigational device or investigational device use. Medtronic will review and decide whether the 
modification(s) will be implemented . 
 
Medtronic will submit an y amendment to the Clinical Investigation Plan, including a justification for such 
amendment, to the investigators to obtain approval from their  IRB. 
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 62 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
   
Any amendment to the protocol requires written approval by [CONTACT_634843] (if 
applicable)  prior to  its implementation unless there are overriding safety reasons. In some instances, an 
amendment may require a change to the ICF.  
 
The Sponsor and Investigator will obtain IRB approval concerning the revised ICF prior to  the 
implementation of the change. The Investigator understands that subjects must be consented using the 
most current IRB approved  version of the ICF. If the ICF is updated, subjects who have participated will be 
re-consented at the direction of the IRB . 
 Recor d Retention  
16.8.1.  Investigator Records  
The investigator is responsible for the preparation and retention of the records cited below. All of the below records, with the exception of case history records and case report forms, should be kept in the 
Investigator Si te File (i.e., the study binder provided to the investigator) or Subject Study Binder. CRFs 
must be maintained and signed electronically within the electronic data capture system during the study. 
The following records are subject to inspection and must be  retained for a period of two years (or longer 
as local law or hospi[INVESTIGATOR_54387]) after product approval or the date on which the 
investigation is terminated.  
• All correspondence between the IRB, sponsor, monitor, RA and the investigator that  
pertains to the investigation, including required reports.  
• Subject’s case history records, including:  
 Signed and dated IC (by [CONTACT_1130] )  
 Observations of AEs /ADEs/DDs  
 Documentation of the dates and rationale for any deviation from the protocol  
• Subject screening log & ID log  
• Normal value(s)/range(s) for clinical laboratory test  
• Lab certificate  
• Device Disposition Logs containing Model and serial numbers of devices delivered to the 
study site, subject IDs of the subjects  
• All approved versions o f the CIP, IC  
• Signed and dated CTA.  
• FD 
• CV of principal investigators and key members of investigation study site team (as required by [CONTACT_5279].  
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 63 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  • Documentation of delegated tasks.  
• IRB approval documentation. Written information that the investigator or other study 
staff, when member of the IRB , did not participate in the approval process. Approval 
documentation must include the IRBs composition, where required per local law.   
• RA notification, correspondence and approval, where required per l ocal law.  
• Study training records for study site staff.  
• Any other records that FDA and local regulatory agencies require to be maintained.  
• Final Study Report including the statistical analysis.  
 
An investigator may withdraw from the responsibility to maintain records for the period required , as 
indicated in  the paragraph above and transfer custody of the records to any other person who will accept  
responsibility. An investigator must notify the Sponsor  if prior  records are being trans ferred .  
16.8.2.  Sponsor Records  
Medtronic shall maintain the following accurate, complete, and current records: 
• All correspondence which pertains to the investigation 
• Investigational device traceability record containing Model and serial numbers of devices, 
shipp ing date and name [CONTACT_634849], location (if 
different than person shipped to), transfer and receipt by [CONTACT_231011]  
• Sample of label attached to investigational device  
• Signed Investigator Trial Agreements, FD and current signed CV of principal investigator [INVESTIGATOR_248937] (as required by [CONTACT_1769]), delegated task list  
• All signed and dated case report forms submitted by [CONTACT_1697], including reports of A es, 
ADEs and DDs (for non-OC studies)  
• All approved IC templates, and other information provided to the subjects and advertisements, including translations  
• Copi[INVESTIGATOR_634814]/roster/letter of a ssurance  
• Names of the institutions in which the study will be conducted  
• RA correspondence, notification and approval as required by [CONTACT_54458]  
• Names/contact [CONTACT_54459]  
• Monitoring visit reports  
• Statistical analyses and underlying supporting data  
• Final report of the study  
• The CIP, Report of Prior Investigations summary and study related reports, and revisions  
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 64 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  • Study training records for study site personnel and Medtronic personnel involved in the 
study  
• Any other records that local regulato ry agencies require to be maintained.  
 
Medtronic records and reports will be maintained in a password -protected document management 
system, and paper documents (where applicable) will be stored in stored in secured file cabinets at 
Medtronic during the course of this study.  
After closure of the study Medtronic could  archive records and reports indefinitely.  
 Reporting Requirements  
16.9.1.  Investigator Reports  
The investigator is responsible for the preparation (review and signature) and submission to the sponsor of all case report forms, adverse events and adverse device effects (reported per the country -specific 
collection requirements), device deficiencies, deaths, and any deviations from the clinical investigation plan.  If any action is taken by [CONTACT_634844], copi[INVESTIGATOR_634815] a timely manner. Reports are subject to inspection and to the retention requirements as described above for investigator records.  
Safety data investigator reporting requirements are listed in Section 12.1. The investigator shall prepare 
and submit in a complete, accurate and timely manner the reports listed in this section.  
Table 7: Investigator reports applicable for all geographies per Medtronic requirements  
Report  Submit to  Description/Constraints  
Withdrawal of IRB 
approval  Sponsor and Relevant 
Authorities  The investigator must report a withdrawal of approval by [CONTACT_634845]’s part of the investigation within [ADDRESS_847826] be submitted within 12 months of study completion or 
termination. 
 Publication and Use of Information  
The Medtronic Publication and Authorship Policy is aligned with the International Committee of Medical  
Journal Editors (ICMJE) recommendations (www.icmje.org). The Sponsor will seek to publish, in  
appropriate peer -reviewed journals and scientific conferences, results of clinical studies where human  
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.[ADDRESS_847827] submit a copy of all  manuscripts and/or abstracts to the 
Sponsor for review and comment 30 days prior to planned  submission. Medtronic acknowledges that its 
right to review and comment shall relate solely to the  proprietary, licensing, and/or confidential rights 
Medtronic may have in such proposed publication,  rather than whether such results and/or opi[INVESTIGATOR_634816].  Authorship on any publication(s) resulting from this clinical study will be assigned 
according to substantial  contributions to conception and design, acquisition of data, or analysis and 
interpretation of data,  drafting the article or revising it critically for important intellectual cont ent and 
final approval of the  version to be published.  
 Medtronic involvement in a publication (e.g., funding of the study; sponsor of the study; collection,  
analysis, and interpretation of data; professional writing assistance) must be disclosed accordin g to  
journal -specific policies, submission requirements, and prevailing editorial standards, in addition to those 
specified by [CONTACT_231016]. The authors must ensure that an  
acknowledgment/disclosure statement is included in the body of the manuscript for Medtronic to  review 
for accuracy. All authors must also disclose financial or personal affiliations that could be  considered 
conflicts of interest as per journal/conference requirements.  
 Medtronic , as the owner of the data , can use the data and/or any results derived from the data or 
publications based on that data for marketing purposes, further research , and development of devices or 
educational use. The study sponsor will collect data in such a way that no subject can be identified and 
monitor study records. Participating subjects will not be identified by [CONTACT_231017] . 
 Suspension or Early Termination  
The Sponsor reserves the right to discontinue the study at any stage, with written notice to all investigators and reviewing IRB. Similarly, investigators may withdraw from the study at any time, subject 
to providing written notification to the Sponsor [ADDRESS_847828] follow -up shall be reported to the Sponsor on the 
appropriate eCRF. 
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 66 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
   
If the study is terminated prematurely or suspended by [CONTACT_456], the sponsor will promptly inform the 
investigators and regulatory authorities (if required) of the termination and the reason(s). The IRB will 
also be promptly informed and provided with the reason(s) for termination or suspension by [CONTACT_634846]. The investigator will promptly inform the subjects  and assure appropriate therapy 
and follow -up for the subject, as needed . 
 If the investigator (or IRB ) terminates or suspends the investigation without  the prior  agreement of the 
sponsor, the investigator will promptly inform the sponsor, the institution (if required) , and the IRB  and 
provide a detailed written explanation of the termination or suspension. The sponsor will inform the regulatory authorities (if required.) 
 In the case  of early termination of the study, all study subjects should be followed until the resolution of 
any pending adverse event(s .) 
 Medtronic reserves the  right to discontinue the study at any time for administrative or other reasons. 
Written notice of study termination will be submitted  to the investigator in advance of such termination. 
Possible reasons for considering study suspension or termination of the study for all centers include but are not limited to:  
• Failure to obtain initial IRB approval or annual renewal of the study ; 
• Consistent non -compliance to the CIP (e.g., failure to adhere to inclusion/exclusion criteria, 
failure to follow subjects per scheduled follow -ups, failure to implement required corrective 
and preventive actions , etc.) ; 
• Lack of enrollment; 
• Noncompliance to regulations and the terms of the Clinical Trial Agreement (e.g., failure to 
submit data in a timely manner, failure to follow -up on data queries and monitoring findings 
in a timely manner, etc.) ; 
• IRB suspension of the center; 
• Fraud or fraudulent misconduct (as defined by [CONTACT_54468]) ; 
• Investigator request (e.g., no longer able to support the study) . 
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 67 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  17. References  
1. Alkire, M.T., A.G. Hudetz, and G. Tononi, Consciousness and Anesthesia.  Science, 2008. 322: p. 
876-880. 
2. Rampil, I.J., A Primer for EEG Signal Processing in Anesthesia. Anesthesiology, 1998. 98(4): p. 
980-1002. 
3. Clark, D.L. and B.S. Rosner, Neurophysiologic effects of general anesthetics. I. The 
electroencephalogram and sensory evoked responses in man.  Anesthesiology, 1973. 36(6): p. 
564-582. 
4. Secretariat, M.A., Bispectral index monitor: an evidence based analysis., O.H.T.A. Series, Editor. 
2004.  
5. Gan, T.J., P.S. Glass, and A. Windsor, Bispectral index monitoring allows faster emergence and improved recovery from propofol, alfentanil, and nitrous oxide anesthesia. BIS Utility Study 
Group.  Anesthesiology, 1997. 87(4): p. 808-815.  
6. Aho, A.J., et al., Comparison of Bispectral Index and Entropy values with electroencephalogram 
during surgical anaesthesia with sevoflurane.  Br J Anaesth, 2015. 115(2): p. [ADDRESS_847829] hesia. A 
randomised clinical trial.  Acta Anaesthesiol Scand, 2013. 57(8): p. 978-87.  
8. Bresson, J., et al., A Randomized Controlled Trial Comparison of NeuroSENSE and Bispectral Brain 
Monitors During Propofol- Based Versus Sevoflurane -Based General Anesthe sia. Anesth Analg, 
2015. 121(5): p. 1194-201.  
9. Brown, C.H.t., et al., Sedation depth during spi[INVESTIGATOR_230941].  Anesth Analg, 2014. 118(5): p. 977-80. 
10. Chan, M.T.V., et al., BIS -guided Ane sthesia Decreases Postoperative Delirium and Cognitive 
Decline.  J Neurosurg Anesthesiol, 2013. 25: p. 33 -42. 
11. Cheung, Y.M., et al., Evaluation of the aepEX monitor of hypnotic depth in pediatric patients 
receiving propofol-remifentanil anesthesia. Paediatr Anaesth, 2013. 23(10): p. 891-7.  
12. Cheung, Y.M., et al., Evaluation of the auditory evoked potentials derived aepEX() as a measure of hypnotic depth in pediatric patients receiving sevoflurane -remifentanil anesthesia. Paediatr 
Anaesth, 2014. 24(7): p . 760 -5. 
13. Conte, V., et al., Bispectral Index During Asleep-Awake Craniotomies.  J Neurosurg Anesthesiol, 
2013(25): p. 279-284.  
14. Frederick, H.J., et al., A Randomized Controlled Trial to Determine the Effect of Depth of Anesthesia on Emergence Agitation in Children.  Anesth Analg, 2016. 122(4): p. 1141-6.  
15. Fritz, B.A., H.R. Maybrier, and M.S. Avidan, Intraoperative electroencephalogram suppression at lower volatile anaesthetic concentrations predicts postoperative delirium occurring in the intensive care unit.  Br J Anaesth, 2018. 121(1): p. 241-248. 
16. Fritz, B.A., et al., ostoperative Recovery with Bispectral Index versus Anesthetic Concentration -
guided Protocols.  ASA publications Anesthesiology 2013. 118(5): p. 1113.  
17. Jindal, A., et al., Bispectral index monitoring for diagnosis and assessment of severity of hepatic encephalopathy in cirrhotic patients.  Dig Liver Dis, 2015. 47(9): p. 769 -74. 
18. Jung, J.Y., C.B. Cho, and B.M. Min, Bispectral index monitoring correlates with the level of 
consciousness in brain injured patients. Korean J Anesthesiol, 2013. 64(3): p. 246 -50. 
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 68 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  19. Kertai, M.D., W.D. White, and T.J. Gan, Cumulative Duration of “Triple Low” State of Low Blood 
Pressure, Low Bispectral Index, and Low Minimum Alveolar Concentration of Volatile Anesthesia 
Is Not Associated with Increased Mortality.  Anesthesiology, 2014(121): p. 18-28. 
20. Lee, S.Y., et al., Comparison of bispectral index scores from the standard frontal sensor position with those from an alternative mandibular position.  Korea n J Anesthesiol, 2014. 66(4): p. 267 -73. 
21. Liu, P.P., et al., The prediction probabilities for emergence from sevoflurane anesthesia in children: A comparison of the perfusion index and the bispectral index.  Paediatr Anaesth, 2018. 
28(3): p. 281-286. 
22. Mei, B., et al., Peripheral Nerve Block as a Supplement to Light or Deep General Anesthesia in Elderly Patients Receiving Total Hip Arthroplasty: A Prospective Randomized Study. Clin J Pain, 
2017. 33(12): p. 1053-1059.  
23. Nitzschke, R., et al., Bispectra l index guided titration of sevoflurane in on-pump cardiac surgery 
reduces plasma sevoflurane concentration and vasopressor requirements: a prospective, controlled, sequential two -arm clinical study.  Eur J Anaesthesiol, 2014. 31(9): p. 482-90.  
24. Orliaguet, G.A., et al., Feasibility of Closed-loop Titration of Propofol and Remifentanil Guided by [CONTACT_231020].  Anesthesiology. 122: p. [ADDRESS_847830] 1: p. i95 -i103.  
26. Sciusco, A., et al., Effect of age on the performance of bispectral and entropy indices during 
sevoflurane pediatric anesthesia: a pharmacometric study.  Paediatr Anae sth, 2017. 27(4): p. 
399-408. 
27. Shan, K., et al., Use of the critical-care pain observation tool and the bispectral index for the 
detection of pain in brain- injured patients undergoing mechanical ventilation: A STROBE -
compliant observational study.  Medic ine (Baltimore), 2018. 97(22): p. e10985.  
28. Shanks, A.M., et al., Alerting thresholds for the prevention of intraoperative awareness with 
explicit recall: a secondary analysis of the Michigan Awareness Control Study.  Eur J Anaesthesiol, 
2015. 32(5): p. 3 46-53.  
29. Short, T.G., et al., Refining Target -Controlled Infusion: An Assessment of Pharmacodynamic 
Target-Controlled Infusion of Propofol and Remifentanil Using a Response Surface Model of Their Combined Effects on Bispectral Index.  Anesth Analg, 2016. 122(1): p. 90 -7. 
30. Shoushtarian, M., et al., Comparisons of Electroencephalographically Derived Measures of Hypnosis and Antinociception in Response to Standardized Stimuli During Target -Controlled 
Propofol -Remifentanil Anesthesia.  Anesth Analg, 2016. 122(2): p. 382 -92. 
31. Subramani, Y., et al., Optimal propofol induction dose in morbidly obese patients: A randomized controlled trial comparing the bispectral index and lean body weight scalar.  Can J Anaesth, 2017. 
64(5): p. 471-479. 
32. Tschiedel, E., et al., Sedation monitoring during open muscle biopsy in children by [CONTACT_231021] - a prospective analysis.  Paediatr Anaesth, 2015. 25(3): p. 265 -71. 
33. Vance, J.L., A.M. Shanks, and D.T. Woodrum, Intraoperative b ispectral index monitoring and 
time to extubation after cardiac surgery: secondary analysis of a randomized controlled trial.  
BMC Anesthesiology, 2014. 14(79): p. [ADDRESS_847831] -track cardiac surgery.  Anesth Analg, 
2013. 116(3): p. 541-8.  
35. Wang, Z.H., et al., Bispectral Index Can Reliably Detect Deep Sedation in Mechanically Ventilated 
Patients: A Prospectiv e Multicenter Validation Study.  Anesth Analg, 2017. 125(1): p. 176-183.  
36. Whitlock, E.L., et al., Postoperative delirium in a substudy of cardiothoracic surgical patients in the BAG -RECALL clinical trial. Anesth Analg, 2014. 118(4): p. 809-17.  
37. Willingham, M.D., et al., Concurrence of Intraoperative Hypotension, Low Minimum Alveolar 
Concentration, and Low Bispectral Index Is Associated with Postoperative Death.  Anesthesiology, 
2015(123): p. 00-85.  
38. Soehle, M., et al., Bilateral bispectral index monitoring during and after electroconvulsive therapy compared with magnetic seizure therapy for treatment-resistant depression.  Br J 
Anaesth, 2014. 112(4): p. 695-702.  
39. Dahaba, A.A., et al., Different Propofol– Remifentanil or Sevoflurane –Remifentanil Bispe ctral 
Index Levels for Electrocorticographic Spi[INVESTIGATOR_230942].  
Anesthesiology, 2013. 119 : p. 582-592. 
40. Sebel, P.S., et al., A Multicenter Study of Bispectral Electroencephalogram Analysis for 
Monitoring Anesthetic Effect. Anesthesia & Analgesia, 1997. 84: p. 891-899.  
41. Kearse, L.A., et al., Bispectral analysis of the electroencephalogram correlates with patient 
movement to skin incision during propofol/nitrous oxide anesthesia.  Anesthesiology, 1994. 
1994(81): p. 365-70. 
42. Vernon, J.M., et al., Prediction of movement using bispectral electroencephalographic analysis 
during propofol/alfentanil or isofurane/alfentanil anesthesia.  Anesth Analg, 1995. 80: p. 780 -5. 
43. Glass, P.S., et al., Bispectral Analysis Measures Sedation and Memory Effects of Propofol, 
Midazolam, Isoflurane, and Alfentanil in Healthy Volunteers  Anesthesiology 1997. 86: p. 836 -
847.  
44. Leslie, K., et al., Prediction of Movement during Propofol/Nitrous Oxide Anesthesia: Performance 
of Concentration, Electroencephalographic, Pupi[INVESTIGATOR_1396], and Hemodynamic Indicators 
Anesthesiology, 1996. 84: p. 52 -63. 
45. Schnider, T.W., et al., The influence of method of administration and covariates on the pharmacokinetics of propofol in adult volunteers.  Anesthesiology, 1998. 88 : p. 1170-82.  
46. Schnider, T.W., et al., The influence of age on propofol pharmacodynamics.  Anesthesiology, 
1999. 90: p. 1502-16. 
47. Minto, C.F., et al., Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development.  Anesthesiology, 1997. 86: p. 10 -23. 
48. Nimmo, A.F., et al., Guidelines for the safe practice of total intravenous anaesthesia (TIVA).  
Anaesthesia, 2019. 74: p. [ADDRESS_847832] -site concentra tion of remifentanil when combined with 
dexmedetomidine in patients undergoing cystoscopy.  Korean J Anesthesiol, 2014. 66(1): p. 39 -
43. 
50. Minto, C.F., T.W. Schnider, and S.L. Shafer, Pharmacokinetics and Pharmacodynamics of Remifentanil: II. Model Application. Anesthesiology 1997. 86: p. 24 -33. 
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 70 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  51. Chernik, D.A., et al., Validity and reliability of the Observer's Assessment of Alertness/Sedation 
Scale: study with intravenous midazolam.  J Clin Psychopharmacol, 1990. 10(4): p. 244-51.  
 
  
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 71 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  18. Appendices  
Appendix A – Modified Observer’s Assessment of Alertness/Sedation 
scale  
 
The Modified Observer Assessment of Alertness/Sedation ( MOAA/S) Scale  [51] 
Respo nse  Score  
Responds readily to name [CONTACT_154992]  5 
Responds lethargically to name [CONTACT_154992]  4 
Responds only after name [CONTACT_231036], repeatedly, or both  3 
Responds only after mild to moderate prodding or shaking  2 
Responds only after painful trapezius squeeze  1 
Does not respond to painful trapezius squeeze  0 
 
Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 74 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
   
 
 
 
 
 
  
 
 
  
  
 
  
   
  
  
   
  
 
  
 
 

Clinical Investigation Plan 
SONORA   
MDT19049SONORA Version  5.0 Page 75 of 75 
 
 
Medtronic Controlled Information  
This document is electronically controlled    056-F275, v  B Clinical Investigation Plan Template  
  
  19. Version History  
Version  Summary of Changes  Author(s)/Title  
1.0 Not Applicable, New Document  Julia Katilius, Ph .D./ 
Sr. Clinical Program Manager  
2.0 Administrative Change Only [IP_ADDRESS]  Julia Katilius, Ph .D./ 
Sr. Clinical Program Manager  
3.0 Administrative Change Date Alignment pg.1 
and pg. 2  / Table 2. Updated CBC to visit 1  Julia Katilius, Ph.D./  
Sr. Clinical Program Manager  
4.[ADDRESS_847833]  
5.0 Change of procedure to increase anesthesia 
until a BIS ™ value of  30 is reach or per 
Investigator’s discretion  
Formatting changes  
Clarification of Statistical Plan  Stephanie Monza, BS CCRC  
Sr. Clinical Research Specialist  
 
 